WO2011034699A2 - Time-division multiplexing in a multi-wavelength photon density wave system - Google Patents
Time-division multiplexing in a multi-wavelength photon density wave system Download PDFInfo
- Publication number
- WO2011034699A2 WO2011034699A2 PCT/US2010/046674 US2010046674W WO2011034699A2 WO 2011034699 A2 WO2011034699 A2 WO 2011034699A2 US 2010046674 W US2010046674 W US 2010046674W WO 2011034699 A2 WO2011034699 A2 WO 2011034699A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- photon density
- density wave
- wavelength
- patient
- time
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/22—Arrangements of medical sensors with cables or leads; Connectors or couplings specifically adapted for medical sensors
- A61B2562/221—Arrangements of sensors with cables or leads, e.g. cable harnesses
- A61B2562/223—Optical cables therefor
Definitions
- the present disclosure relates generally to non-invasive measurement of physiological parameters and, more particularly, to multi-wavelength photon density wave measurements of physiological parameters.
- Pulse oximetry may be defined as a non-invasive technique that facilitates monitoring of a patient's blood flow characteristics. For example, pulse oximetry may be used to measure blood oxygen saturation of hemoglobin in a patient's arterial blood and/or the patient's heart rate. Specifically, these blood flow characteristic measurements may be acquired using a non-invasive sensor that passes light through a portion of a patient's tissue and photo-electrically senses the absoiption and scattering of the light through the tissue. Typical pulse oximetry technology may employ two light emitting diodes (LEDs) and a single optical detector to measure pulse and oxygen saturation of a given tissue bed.
- LEDs light emitting diodes
- a typical signal resulting from the sensed light may be referred to as a plethysmograph waveform.
- Such measurements are largely based on absorption of emitted light by specific types of blood constituents. Once acquired, this measurement may be used with various algorithms to estimate a relative amount of blood constituent in the tissue. For example, such measurements may provide a ratio of oxygenated hemoglobin to total hemoglobin in the volume being monitored.
- the amount of arterial blood in the tissue is generally time-varying during a cardiac cycle, which is reflected in the plethysmographic waveform.
- the accuracy of blood flow characteristic estimation via pulse oximetry may depend on a number of factors. For example, variations in light absoiption
- characteristics can affect accuracy depending on where the sensor is located and/or the physiology of the patient being monitored. Additionally, various types of noise and interference can create inaccur acies. For example, electrical noise, physiological noise, and other interference can contribute to inaccurate blood flow characteristic estimates.
- a multi-wavelength system may include a sensor, a sensor cable, and a patient monitor.
- the sensor may have an emitter output and a detector input configured to pass a multi-wavelength photon density wave input signal into a patient and receive a resulting multi-wavelength photon density wave output signal.
- the sensor cable may couple to the sensor using two optical cables for transmitting and receiving the multi-wavelength photon density wave signals.
- the patient monitor may couple to the sensor cable and generate several time-division multiplexed single-wavelength input signals by modulating one or more light sources at a frequency sufficient to produce resolvable photon density waves in the patient. By combining the several time-division multiplexed single-wavelength input signals into one of the optical cables of the sensor cable, the patient monitor may generate the multi- wavelength photon density wave input signal.
- FIG. 1 is a perspective view of a pulse oximeter system in accordance with an embodiment
- FIG. 2 is a block diagram of the pulse oximeter system of FIG. 1, in accordance with an embodiment
- FIG. 3 is a plot of a first single- avelength photon density wave signal for use in the system of FIG. 1, in accordance with an embodiment
- FIG. 4 is a plot of a second single-wavelength photon density wave signal for use in the system of FIG. 1, in accordance with an embodiment
- FIG. S is a plot of a multi-wavelength photon density wave signal combining the first and second single-wavelength photon density wave signals of FIGS. 3 and 4, in accordance with an embodiment
- FIG. 6 is a plot representing a comparison between a portion of the multi- wavelength photon density wave signal of FIG. 5 and a received single-wavelength photon density wave signal after the signal of FIG, 5 has been passed through a patient, in accordance with an embodiment
- FIG. 7 is a flowchart representing an embodiment of a method for obtaining physiological measurements using the system of FIG. 1 , in accordance with an embodiment
- FIG. 8 is a flowchart representing an embodiment of an algorithm for use by the system of FIG. 1 for determining scattering and absoiption properties of patient tissue.
- Present embodiments relate to non-invasively measuring physiological parameters corresponding to blood flow in a patient.
- light may be emitted into a patient and photoelectrical ly detected after having passed through pulsatile patient tissue.
- present embodiments involve modulating the light at frequencies sufficient to produce waves of photons known as photon density waves in the tissue.
- the photon density waves may propagate through the pulsatile tissue of the patient, undergoing refraction, diffraction, interference, dispersion, attenuation, and so forth.
- Multiple photon density wave signals of various wavelengths of light may be time-division multiplexed at a patient monitor into a single emission optical cable and provided to a sensor attached to a patient.
- a multi- wavelength photon density wave signal emitted into pulsatile patient tissue, may be recovered by the sensor after reflection or transmission through the tissue.
- a single detection optical cable may cany the received signal to the patient monitor. Since the multi-wavelength photon density wave signal is time-division multiplexed, a single detector may photoelectrical ⁇ detect and digitize the received signal. The detected and digitized multi-wavelength signal may be demultiplexed into its component single-wavelength signals.
- Each of the received and detected single- wavelength photon density wave signals may be analyzed to obtain scattering and absorption properties of the pulsatile patient tissue.
- a change in phase of a photon density wave signal passed through the patient tissue may correspond to scattering components of the tissue, while a change in amplitude may correspond to absorptive components in the tissue.
- the scattering coefficient may change over time depending on a total quantity of hemoglobin in the tissue
- variations in phase changes may correspond to variations in total hemoglobin.
- such changes in phase over time may be due predominantly to the total number of scattering particles (e.g., total hemoglobin), and not merely a ratio of particles (e.g., oxygenated and total hemoglobin).
- Changes in amplitude of the photon density wave signals may correspond to the absorptive components of the pulsatile patient tissue, not scattering components. Certain components of the tissue may absorb different wavelengths of light, such as red or infrared light, in different amounts. By analyzing decreases in amplitudes of the received single- wavelength photon density wave signals, a ratio of different types of particles in the pulsatile patient tissue, such as oxygenated and deoxygenated hemoglobin, may be estimated. With measurements of scattering and absorption characteristics of the tissue, physiological parameters such as Sp02, regional oxygen saturation, total hemoglobin, perfusion, and many others may be obtained.
- FIG. 1 illustrates a perspective view of a photon density wave pulse oximetry system 10, which may include a patient monitor 12 and a pulse oximeter sensor 14.
- a sensor cable 16 may connect the patient monitor 12 to the sensor 14, and may include two fiber optic cables.
- One of the fiber optic cables within the sensor cable 16 may transmit a multi-wavelength photon density wave input signal from the patient monitor 12 to the sensor 14, and another of the fiber optic cables may transmit a multi-wavelength photon density wave output signal from the sensor 14 to the patient monitor 12.
- the cable 16 may couple to the monitor 12 via an optical connection 18.
- the patient monitor 12 may determine certain physiological parameters that may appeal- on a display 20. Such parameters may include, for example, a plethysmogram or numerical representations of patient blood flow (e.g., partial oxygen saturation or a measurement of total hemoglobin).
- the patient monitor 12 may modulate light sources of two or more wavelengths at modulation frequencies of approximately 50 MHz - 3GHz, which may produce resolvable photon density wave signals in pulsatile tissue because the resulting photon density waves at such frequencies may have wavelengths shorter than a mean absorption distance in pulsatile tissue.
- the patient monitor 12 may sweep the modulation frequency of one or more of the light sources in a range from 50 MHz to 2.4 GHz.
- Some embodiments of the patient monitor 12 may be configured to modulate between 100 MHz and 1 GHz or to sweep a range from 100 MHz to 1 GHz.
- the patient monitor 12 may, in certain embodiments, modulate the light sources primarily at a frequency of approximately 500 MHz. Examples of such single- wavelength photon density wave signals that may be generated by the patient monitor 12 may be illustrated below with reference to FIGS. 3 and 4.
- the patient monitor 12 may time-division multiplex these several single- wavelength photon density wave signals into a single multi-wavelength photon density signal, in which each of the single-wavelength photon density wave signals is alternatingly the sole wavelength active in the multi-wavelength signal for brief periods of time (e.g., approximately 150 ns to several ms). Generally, these periods of time may be brief enough to enable each of the single-wavelength components of the multi- wavelength signal to pass through the pulsatile tissue at substantially the same time.
- the periods of time may be brief enough such that, for purposes of pulse oximetry, substantially no perceptible change in the pulsatile tissue of the patient may occur between the start of the first single-wavelength component and the start of the last single-wavelength component in the multi-wavelength signal.
- An example of such a multi-wavelength signal composed of time-division multiplexed single-wavelength signals may be illustrated below with reference to FIG. 5.
- the multi-wavelength signal may be provided to the sensor 14 via the sensor cable 16.
- the sensor 14 may include an emitter output 22 and a detector input 24.
- the emitter output 22 may guide the multi-wavelength photon density wave signal from the sensor cable 16 to enter pulsatile tissue of a patient 26.
- the detector input 24 may receive the resulting multi-wavelength photon density signal from the pulsatile tissue of the patient 26 and guide the received signal back to the patient monitor 12 via the sensor cable 16.
- the sensor 14 may be, for example, a reflectance-type sensor or a
- Wave characteristics of the received single- wavelength photon density signals may be measured in accordance with present embodiments, and may include characteristics that relate predominantly to absorption of the emitted light in the probed medium (e.g., amplitude change) and characteristics that relate predominantly to scattering in the probed medium (e.g., phase shift).
- the correlation of certain wave characteristic (e.g., amplitude and phase) measurements to certain medium characteristics (e.g., quantity of scattering particles and blood oxygen saturation) may depend on the modulation of the light sources within the patient monitor, which may generate resolvable photon density waves.
- the modulation frequency of such signals should produce photon density waves having modulation wavelengths that are shorter than a mean absorption distance of the probed tissue medium.
- the system 10 may be utilized to make measurements that relate predominantly to scattering in the observed volume. More specifically, the system 10 may be utilized to make measurements relating to a total amount of scattering particles in the observed volume based on phase shifts detected in the emitted light waves. For example, the system 10 may emit light that is modulated at a frequency (e.g., 50 MHz to 3 GHz) sufficient to generate resolvable photon density waves, and then measure the phase shift of these waves to facilitate estimation of a total number of scattering particles in the observed medium. Similarly, as set forth above, the system 10 may be utilized to make measurements that relate predominantly to absorption in an observed volume.
- a frequency e.g., 50 MHz to 3 GHz
- the system 10 may detect changes in AC and DC amplitudes of the resolvable photon density waves to facilitate detection of a ratio of certain constituents in the blood (e.g., a ratio of oxygenated to total hemoglobin).
- a ratio of certain constituents in the blood e.g., a ratio of oxygenated to total hemoglobin.
- the amplitude changes and phase shifts measured at a detection point may be considered relative to one or more points.
- the amplitude and phase shifts measured from the detector input 24 may be considered relative to the associated values generated at the emitter output 22.
- FIG. 2 represents a block diagram of the system 10 of FIG. 1.
- the patient monitor 12 may generate several single-wavelength photon density wave signals at alternating periods of time (e.g., between approximately every 150 ns and several ms) using a driving circuit 28, such that generally only one single-wavelength photon density wave signal is active at any given time.
- the period of time that each single-wavelength photon density wave is active may be short enough such that only very slight changes occur in patient 26 pulsatile tissue content.
- the alternating pulses of the several single-wavelength signals may occur close enough to one another such that, for medical purposes, they occur at substantially the same time.
- the driving circuit 28 may include one or more light sources that may emit at least two different wavelengths of light. Such wavelengths may include red wavelengths of between approximately 600-700 nm and/or infrared wavelengths of between approximately 800- 1000 nm .
- the light sources of the driving circuit 28 may be laser diodes that emit red or infrared light with wavelengths of approximately 660 nm or 808 nm, respectively.
- the one or more light sources of the driving circuit 28 may emit three or more different wavelengths light.
- Such wavelengths may include a red wavelength of between approximately 620-700 nm (e.g., 660 nm), a far red wavelength of between approximately 690-770 nm (e.g., 730 nm), and an infrared wavelength of between approximately 860-940nm (e.g., 900 nm).
- Other wavelengths that may be emitted by the one or more light sources of the driving circuit 28 may include, for example, wavelengths of between approximately 500-600 nm and/or 1000-1100 nm.
- the driving circuit 28 may modulate these light sources at a modulation frequency between approximately 50 MHz to 3 GHz. Such modulation frequencies may suffice to produce resolvable photon density waves when emitted into pulsatile tissue of the patient 26, since corresponding wavelengths of the photon density waves may be shorter than a mean distance of absorption in the tissue.
- the modulation frequency of each light source may vaiy, as one light source may have a higher or lower modulation frequency than another light source.
- the driving circuit 28 may represent one or more components of commonly available drive circuits (e.g., DVD R W driver circuits) for modulation. Examples of such devices may include the LMH6525 device available from National Semiconductor Inc.
- the driving circuit 28 is illustrated to generate two single-wavelength photon density wave signals of different wavelengths respectively through an optical cable 30 and an optical cable 32.
- the driving circuit 28 may be designed to generate any suitable number of single- wavelength signals.
- a fiber coupler 34 may join the two optical cables 30 and 32 together, multiplexing the two single-wavelength photon density wave signals into one multi-wavelength photon density wave signal.
- This multi-wavelength photon density wave signal may represent a combination of the several single-wavelength photon density wave signals generated at alternating periods of time by the driving circuit 28 and, as such, may be understood to represent a time-division multiplexed combination of the several single-wavelength photon density wave signals.
- An optical cable 36 may carry the multi-wavelength photon density wave signal through the sensor cable 16 to the emitter output 22 of the sensor 14.
- the multi- wavelength photon density wave signal may thereafter enter pulsatile tissue of the patient 26, where the signal may be scattered and absorbed by various components of the tissue.
- the detector input 24 may receive and guide the portion of the signals reflected or transmitted through the patient 26 tissue to the patient monitor 12 over an optical cable 38, which may be a second of only two optical cables of the sensor cable 16. Because the multi-wavelength signal represents a time-division multiplexed combination of the several single-wavelength photon density wave signals, only one of the single-wavelength signals generally may pass through the patient 26 and the optical cable 38 at any given time.
- the received multi-wavelength photon density wave generally may be photoelectrical ly detected in a single photodetector 40, which may receive and convert the optical signal to an electrical signal, before amplifying the received signal.
- a single photodetector 40 may receive and convert the optical signal to an electrical signal, before amplifying the received signal.
- two or more single-wavelength signals may be passed through the patient 26 at once and wavelength demultiplexed before the overall multi-wavelength photon density wave signal may be time-division demultiplexed.
- the resulting signal may enter phase detection circuitry 42, and the output of the phase detection circuitry 42 may be digitized and entered into a processor, such as a digital signal processor (DSP) 44, to be analyzed for phase and amplitude changes.
- a processor such as a digital signal processor (DSP) 44
- the driving circuit 28 may provide the phase detection circuitry 42 and the DSP 46 with time-division information to indicate which single-wavelength photon density wave signal is currently being received. Using such time-division information, the phase detection circuitry 42 and the DSP 46 may demultiplex the time-division multiplexed multi-wavelength photon density wave signal into its component single- wavelength signal segments.
- the phase detection circuitry 42 may obtain the received multi-wavelength photon density wave signal from the detector 40, and time-division information, clock signals, and/or reference signals relating to the corresponding original emitted single-wavelength photon density wave signals from the driving circuitry 28. The phase detection circuitry 42 may thereafter detect phase changes between the original emitted signal and the received signal associated with each wavelength.
- the phase detection circuitry 42 and the driving circuit 28 may be individual components of a single semiconductor device, such as a DVD R/W driver circuit. Such devices may include the L H6525 device available from National Semiconductor Inc.
- the DSP 44 may receive the output from the phase detection circuitry 42 and time-division information and/or reference signal information from the driver circuit 28. By comparing amplitude changes between the received photon density wave signals and the corresponding emitted photon density wave signals of the same corresponding wavelength of light, absorption properties of the patient 26 tissue for each wavelength of light may be determined. Using the absorption and scattering information associated with the amplitude changes and phase changes of the photon density wave signals passed through the patient 26, the DSP 44 may determine a variety of properties based on algorithms stored in memory on the DSP 44 or received from external sources, such as a microprocessor 46 or other devices via a bus 48. One example of such an algorithm may be described below with reference to FIG. 8.
- the DSP 44 may ascertain certain properties of the patient 26 tissue based on the following relationships described below.
- the change in phase ⁇ between two points located a distance r from each other on a tissue bed may be given by the following relation:
- ⁇ is the angular frequency of modulation
- ⁇ is the reduced scattering coefficient.
- the reduced scattering coefficient for a tissue bed accounts for both blood and surrounding tissue components. This can be written as:
- the time varying component of this equation at a single wavelength will generally be only the portion due to arterial blood.
- the time varying component of this equation at a second wavelength will allow for the deconvolution of the scattering coefficient.
- the scattering coefficient for blood is related to the hematocrit (HCT) through the following relation:
- g is the anisotropy factor
- ⁇ is the scattering cross section of an erythrocyte
- Vi is the volume of an erythrocyte
- HCT is the hematocrit
- the phase of the photon density waves may be sensitive to changes in the scattering coefficient, while the amplitude of the photon density waves may be sensitive to the concentration of absorbers in the medium.
- the AC amplitude and DC amplitude may yield information about absorption in the volume.
- detection of amplitude changes in the photon density waves may be utilized to calculate absorber concentration values in the observed medium, such as blood oxygen saturation values.
- Such calculations may be made using a standard ratio of ratios (e.g., ratrat) technique for the constant and modulated values of the photon density wave amplitudes at two wavelengths. Once the ratio of ratios values is obtained, it may be mapped to the saturation from clinical calibration curves.
- the amplitude of the resulting photon density waves after passing through the patient 26 tissue may be described as follows:
- a 0 is the initial amplitude
- D is the diffusion coefficient given as is the absoiption coefficient
- r sd is the distance between the
- phase shift measurements when the wavelength of the photon density waves is less than a mean absorption distance of the pulsatile tissue of the patient 26, the phase becomes almost exclusively a function of the scattering coefficient. While dependent upon the tissue bed being probed, this is generally believed to occur at a modulation frequency in the range of approximately 500 MHz.
- the phase shift measurement may yield information about the number of erythrocytes or red blood cells in the local probed volume.
- the HCT discussed above is proportional to the number of erythrocytes. Accordingly, by sweeping frequencies, a multi-parameter output may be obtained that relates to standard pulse oximetry measurements as well as the puddle hematocrit.
- the change in phase of the resulting photon density waves after passing through the patient 26 tissue may be described as follows:
- the amplitude and phase at a given frequency may be proportional to the scattering and absorption coefficient at a given wavelength until the product of the frequency and the mean time between absorption events is much larger than 1.
- the amplitude is a function of the absoiption and phase is only a function of the scattering.
- the driving circuit 28 may perform a frequency sweep over time (e.g., from 100 MHz to 1 GHz) to reduce the error in the determination of a single value of reduced scattering coefficient for the blood and a single value of absoiption coefficient.
- present embodiments may provide an extra degree of certainty for blood flow parameter measurements.
- the detected amplitude for the photon density waves may be utilized to calculate traditional pulse oximetry information and the phase may be utilized to con irm that such values are correct (e.g., within a certain range of error).
- the amplitude information may be utilized to calculate a blood oxygen saturation (SpC ⁇ ) value and empirical data may indicate that a particular SpC>2 value should correspond to a particular phase variation at a given frequency.
- SpC ⁇ blood oxygen saturation
- phase change there may be a certain phase change that should accompany a given increase in absorber observed as a change in amplitude.
- Various known techniques e.g., learning based algorithms such as support vector machines, cluster analysis, neural networks, and PCA
- learning based algorithms such as support vector machines, cluster analysis, neural networks, and PCA
- the measured SpC>2 value may be deemed appropriate and displayed or utilized as a correct Sp02 value.
- the calculated S C value may be identified as being corrupt or including too much noise and, thus, may be discarded.
- the patient monitor 12 may include a general- or special- purpose microprocessor 46 on the bus 48, which may govern other general operations of the patient monitor 12, such as how data from the DSP 44 is employed by other components on the bus 48.
- a network interface card (NIC) 50 may enable the patient monitor 12 to communicate with external devices on a network.
- NIC network interface card
- a read only memoiy (ROM) 52 may store certain algorithms, such as those used by the DSP 44 to determine absoiption and scattering properties of the patient 26 tissue, and nonvolatile storage 54 may store longer long-term data. Additionally or alternatively the nonvolatile storage 54 may also store the algorithms for determining tissue properties.
- Other components of the patient monitor 12 may include random access memory
- the RAM 56 may provide temporary storage of variables and other data employed while carry out certain techniques described herein, while the display interface 58 may allow physiological parameters obtained by the patient monitor 12 to appear on the display 20.
- the control inputs 60 may enable a physician or other medical practitioner to vary the operation of the patient monitor 12. By way of example, a practitioner may select whether the patient 26 is an adult or neonate, and/or whether the tissue is high perfusion or low perfusion tissue. Such a selection with the control inputs 60 may vary the modulation frequency of one or more of the single-wavelength photon density wave signals, may disable one or more of the single-wavelength photon density wave signals, or may cause a
- preprogrammed sequence of operation such as a sweep of modulation frequencies for one or more of the single-wavelength photon density wave signals, to begin.
- the driving circuit 28 may emit several single-wavelength photon density wave signals that may be combined in the fiber coupler 34 into one multi- wavelength photon density wave signal and sent to the sensor 14.
- a plot 62 may describe an embodiment of one single- wavelength component of such a multi-wavelength photon density wave signal.
- an ordinate 64 represents relative amplitude
- an abscissa 66 represents relative time.
- Numeral 68 refers to a first single- wavelength photon density wave signal (e.g., a 660 nm photon density wave signal) generated by the driving circuit 28. It should be understood that the signal 68 may alternatively have a different amplitude, modulation frequency, and/or phase.
- the single-wavelength signal 68 may be active at regular intervals for a given period of time (e.g., between approximately 150 ns and 1 ms) for time-division multiplexing with one or more other signals. As noted below with reference to FIGS. 4 and 5, the single-wavelength photon density wave signal 68 may be combined with other single-wavelength signals into a multi-wavelength signal. The driving circuit 28 may thus emit the signal 68 at intervals and for periods of time related to the number of other emitted single-wavelength signals to be combined into the multi-wavelength signal.
- the single- wavelength photon density wave signal 68 is one of two single- wavelength photon density wave signals emitted by the driving circuit 28, the signal 68 may be emitted by the driving circuit 28 approximately half of the time, as shown in the plot 62.
- FIG. 4 is a plot 70 that may describe an embodiment of another single- wavelength component of a multi-wavelength photon density wave signal.
- an ordinate 72 represents relative amplitude
- an abscissa 74 represents relative time.
- Numeral 76 refers to a second single-wavelength photon density wave signal (e.g., an 808 nm photon density wave signal) generated by the driving circuit 28.
- the single- wavelength signal 76 may be active at regular intervals for a given period of time (e.g., between approximately 150 ns and 1 ms) for time-division multiplexing with one or more other photon density wave signals, such as the single-wavelength photon density wave signal 68.
- the signal 76 may be active at times when the signal 68 of the plot 62 is not. It should be understood that the signal 76 may alternatively have a different amplitude, modulation frequency, and/or phase.
- the single-wavelength photon density wave signals 68 and 76 emitted by the driving circuitry 28 may be combined into a single multi-wavelength photon density wave signal in the fiber coupler 38.
- FIG. 5 represents a plot 78 illustrating such a multi- wavelength photon density wave signal having time-division multiplexed single- wavelength component signals 68 and 76.
- an ordinate 80 represents relative amplitude
- an abscissa 82 represents relative time.
- the signals 68 and 76 may occur at different, non-overlapping, times in the multi-wavelength signal of the plot 78. In this way, the two single-wavelength photon density wave signals 68 and 76 may be later separated into distinct single-wavelength signals with time-division
- a brief dark period 84 may separate the two signals 68 and 76.
- single-wavelength component output signals resulting from the signals 68 and 76, may be isolated in the phase detection circuitry 42 and the DSP 44 with time-division information the driving circuit 28.
- Compaving one of the single-wavelength output signals with the corresponding original single- wavelength signal 68 or 76 of the plot 78 may indicate various properties of the patient 26 tissue.
- FIG. 6 illustrates the superimposition of a single- wavelength segment of the signal 68 from the multi-wavelength plot 78 with the resulting single- wavelength signal detected after passage through the patient 26.
- plot 86 of FIG. 6 includes an ordinate 88 representing relative amplitude and an abscissa 90 representing time in units of nanoseconds (ns).
- the input single-wavelength photon density wave signal 68 and a corresponding output single- wavelength photon density wave signal 80 may have a DC amplitude difference of ⁇ DC 1 , an AC amplitude difference of A4C, , and a phase difference of ⁇ 1 .
- the amplitude measurements ⁇ DC 1 and ⁇ AC 1 may correspond essentially only to absorption in the patient 26 tissue, while the phase difference ⁇ 1 may correspond essentially only to scattering in the patient 26 tissue, as generally described with reference to FIG. 8 below. Since another single-wavelength photon density wave signal, such as the single- wavelength signal 76, may occur very shortly thereafter, performing a similar comparison with the other single-wavelength signal may yield additional measurements for absoiption and scattering properties of the patient 26 for the second wavelength, at substantially the same time. Thus, the patient monitor 12 may determine at least four measurements associated with properties of the patient 26 tissue for substantially the same time for medical purposes associated with pulse oximetry, including two absorption and two scattering properties.
- FIG. 7 illustrates a flowchart 94, which represents an embodiment of a method for performing photon density wave measurements using two wavelengths of light.
- the driving circuit 28 may modulate a light source emitting a first wavelength (e.g., a 660 nm wavelength) at a modulation frequency sufficient to produce resolvable photon density waves within the patient 26 for a brief period of time (e.g., between approximately 150 ns and 1 ms).
- the period of time may depend, for example, on the modulation frequency or the number of wavelengths of light that the driving circuit 28 will modulate.
- the modulation frequency may result in a photon density wave wavelength shorter than a mean absorption distance of the pulsatile tissue of the patient 26.
- such modulation frequency may exceed the product of the mean absorption coefficient multiplied by the speed of light.
- the modulation frequency may be between 50 MHz to 3 GHz.
- the light source may be modulated at a frequency of approximately 500 MHz.
- the first single-wavelength photon density wave signal may enter the fiber coupler 34 before being transmitted to the sensor 14 via the optical cable 36. Only the first single-wavelength signal may travel across the optical cable 36 at this time.
- the first single-wavelength photon density wave signal may enter pulsatile tissue of the patient 26 through the emitter output 22 of the sensor 14. After the signal has been reflected or transmitted through the patient 26 tissue, the detector input 24 of the sensor 14 may receive and guide the signal to the optical cable 38, which may transmit the signal back to the patient monitor 12.
- step 102 The output single-wavelength photon density wave signal that results when the first single-wavelength photon density wave signal is passed through the patient 26 may be detected in the detector 40 in step 100.
- the phase detection circuitry 44 may determine phase changes between the output single-wavelength photon density wave signal and the corresponding input single-wavelength photon density wave signal, and the DSP 46 may determine amplitude changes.
- the DSP 46 and/or microprocessor 48 may thereafter determine various scattering and absorption properties of the patient 26 tissue, since changes in phase may correspond to scattering in the patient 26 tissue, while changes in amplitude may correspond to absoiption. It should be appreciated that step 102 may occur any time after steps 96-100, including concurrently with or after steps 104-108 described below.
- Step 104 may generally begin substantially immediately after step 100.
- the driving circuit 28 may modulate a light source emitting a second wavelength in substantially the same manner as in step 96 to produce a second single-wavelength photon density wave signal.
- the second single- wavelength photon density wave signal may be passed through the patient 26, and in step 108, the output second single-wavelength photon density wave signal may be detected in the detector 40.
- Step 110 may involve ascertaining phase and amplitude changes between the output second single- wavelength photon density wave signal and the corresponding input single- wavelength photon density wave signal in substantially the same manner as step 102. Step 110 may occur time after steps 104-108.
- the flowchart 94 may repeat indefinitely, with step 96 generally beginning after step 108.
- the modulation frequency may or may not vaiy among the light sources and may or may not vary over time. Because both the first and second single-wavelength signals may travel across the optical cable 36, but at distinct times, the two signals of different wavelengths may be understood to be time-division multiplexed and may be understood collectively to form a multi-wavelength photon density wave signal.
- FIG. 8 is a flowchart 110, which represents an algorithm that may be used by a processor, such as the DSP 44 of the patient monitor 12, to determine physiological properties of the patient 26 tissue using values obtained by passing a multi-wavelength photon density wave signal through the patient 26 tissue.
- a processor such as the DSP 44 of the patient monitor 12
- the flowchart 110 may generally begin after all or part of the flowchart 94 of FIG. 7 has been carried out.
- phase change ⁇ 1 and/or amplitude change ⁇ DC, 1 and/or ⁇ AC 1 values for one of the single-wavelength components of the multi-wavelength photon density wave signal may be received into or determined by a processor, such as the DSP 44.
- the DSP 44 may determine a scattering property of the patient 26 tissue for the moment in time at which the single-wavelength component of the multi- wavelength photon density wave signal has passed through the pulsatile tissue of the patient 26.
- the scattering property may be represented by a scattering coefficient, and may be determined based on the phase change ⁇ 1 value obtained in step 112 by using Equation (1).
- the DSP 44 may determine an absorption property of the patient 26 tissue for the moment in time at which the single-wavelength component of the multi- wavelength photon density wave signal has passed through the pulsatile tissue of the patient 26.
- the absorption property may be represented by an absorption coefficient, and may be determined based on the amplitude change ⁇ DC 1 and/or ⁇ DC 1 values obtained in step 112 by using Equations (1) and (4).
Abstract
Multi-wavelength photon density wave medical systems, methods, and devices are provided. In one embodiment, a multi-wavelength system may include a sensor, a sensor cable, and a patient monitor. The sensor may have an emitter output and a detector input configured to pass a multi-wavelength photon density wave input signal into a patient and receive a resulting multi-wavelength photon density wave output signal. The sensor cable may couple to the sensor using two optical cables for transmitting and receiving the multi-wavelength photon density wave signals. The patient monitor may couple to the sensor cable and generate several time-division multiplexed single-wavelength input signals by modulating one or more light sources at a frequency sufficient to produce resolvable photon density waves. By combining the several time-division multiplexed single-wavelength input signals into one of the optical cables of the sensor cable, the patient monitor may generate the multi-wavelength photon density wave input signal.
Description
TIME-DIVISION MULTIPLEXING IN A MULTI-WAVELENGTH PHOTON DENSITY WAVE SYSTEM
BACKGROUND
The present disclosure relates generally to non-invasive measurement of physiological parameters and, more particularly, to multi-wavelength photon density wave measurements of physiological parameters.
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present disclosure, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present disclosure. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
Pulse oximetry may be defined as a non-invasive technique that facilitates monitoring of a patient's blood flow characteristics. For example, pulse oximetry may be used to measure blood oxygen saturation of hemoglobin in a patient's arterial blood and/or the patient's heart rate. Specifically, these blood flow characteristic measurements may be acquired using a non-invasive sensor that passes light through a portion of a patient's tissue and photo-electrically senses the absoiption and scattering of the light through the tissue. Typical pulse oximetry technology may employ two light emitting diodes (LEDs) and a single optical detector to measure pulse and oxygen saturation of a given tissue bed.
A typical signal resulting from the sensed light may be referred to as a plethysmograph waveform. Such measurements are largely based on absorption of
emitted light by specific types of blood constituents. Once acquired, this measurement may be used with various algorithms to estimate a relative amount of blood constituent in the tissue. For example, such measurements may provide a ratio of oxygenated hemoglobin to total hemoglobin in the volume being monitored. The amount of arterial blood in the tissue is generally time-varying during a cardiac cycle, which is reflected in the plethysmographic waveform.
The accuracy of blood flow characteristic estimation via pulse oximetry may depend on a number of factors. For example, variations in light absoiption
characteristics can affect accuracy depending on where the sensor is located and/or the physiology of the patient being monitored. Additionally, various types of noise and interference can create inaccur acies. For example, electrical noise, physiological noise, and other interference can contribute to inaccurate blood flow characteristic estimates.
SUMMARY
Certain aspects commensurate in scope with the originally claimed embodiments are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the embodiments might take and that these aspects are not intended to limit the scope of the presently disclosed subject matter. Indeed, the embodiments may encompass a variety of aspects that may not be set forth below.
Present embodiments relate to multi-wavelength photon density wave medical systems, methods, and devices. In one embodiment, a multi-wavelength system may include a sensor, a sensor cable, and a patient monitor. The sensor may have an emitter
output and a detector input configured to pass a multi-wavelength photon density wave input signal into a patient and receive a resulting multi-wavelength photon density wave output signal. The sensor cable may couple to the sensor using two optical cables for transmitting and receiving the multi-wavelength photon density wave signals. The patient monitor may couple to the sensor cable and generate several time-division multiplexed single-wavelength input signals by modulating one or more light sources at a frequency sufficient to produce resolvable photon density waves in the patient. By combining the several time-division multiplexed single-wavelength input signals into one of the optical cables of the sensor cable, the patient monitor may generate the multi- wavelength photon density wave input signal.
BRIEF DESCRIPTION OF THE DRAWINGS
Advantages of the presently disclosed subject matter may become apparent upon reading the following detailed description and upon reference to the drawings in which:
FIG. 1 is a perspective view of a pulse oximeter system in accordance with an embodiment;
FIG. 2 is a block diagram of the pulse oximeter system of FIG. 1, in accordance with an embodiment;
FIG. 3 is a plot of a first single- avelength photon density wave signal for use in the system of FIG. 1, in accordance with an embodiment;
FIG. 4 is a plot of a second single-wavelength photon density wave signal for use in the system of FIG. 1, in accordance with an embodiment;
FIG. S is a plot of a multi-wavelength photon density wave signal combining the first and second single-wavelength photon density wave signals of FIGS. 3 and 4, in accordance with an embodiment; FIG. 6 is a plot representing a comparison between a portion of the multi- wavelength photon density wave signal of FIG. 5 and a received single-wavelength photon density wave signal after the signal of FIG, 5 has been passed through a patient, in accordance with an embodiment;
FIG. 7 is a flowchart representing an embodiment of a method for obtaining physiological measurements using the system of FIG. 1 , in accordance with an embodiment; and
FIG. 8 is a flowchart representing an embodiment of an algorithm for use by the system of FIG. 1 for determining scattering and absoiption properties of patient tissue. DETAILED DESCRIPTION
One or more specific embodiments of the present disclosure will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-speci ic decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another.
Moreover, it should be appreciated that such a development effort might be complex and
time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
Present embodiments relate to non-invasively measuring physiological parameters corresponding to blood flow in a patient. Specifically, light may be emitted into a patient and photoelectrical ly detected after having passed through pulsatile patient tissue. Rather than send a light signal modulated at a rate that is effectively DC through the pulsatile patient tissue, present embodiments involve modulating the light at frequencies sufficient to produce waves of photons known as photon density waves in the tissue. The photon density waves may propagate through the pulsatile tissue of the patient, undergoing refraction, diffraction, interference, dispersion, attenuation, and so forth. These effects may vary depending on the current composition of the patient tissue, which in turn may vary as blood enters and exits the tissue.
Multiple photon density wave signals of various wavelengths of light may be time-division multiplexed at a patient monitor into a single emission optical cable and provided to a sensor attached to a patient. Such a multi- wavelength photon density wave signal, emitted into pulsatile patient tissue, may be recovered by the sensor after reflection or transmission through the tissue. Thereafter, a single detection optical cable may cany the received signal to the patient monitor. Since the multi-wavelength photon density wave signal is time-division multiplexed, a single detector may photoelectrical^ detect and digitize the received signal. The detected and digitized multi-wavelength signal may be demultiplexed into its component single-wavelength signals.
Each of the received and detected single- wavelength photon density wave signals may be analyzed to obtain scattering and absorption properties of the pulsatile patient tissue. In particular, a change in phase of a photon density wave signal passed through
the patient tissue may correspond to scattering components of the tissue, while a change in amplitude may correspond to absorptive components in the tissue. For example, since the scattering coefficient may change over time depending on a total quantity of hemoglobin in the tissue, variations in phase changes may correspond to variations in total hemoglobin. Thus, such changes in phase over time may be due predominantly to the total number of scattering particles (e.g., total hemoglobin), and not merely a ratio of particles (e.g., oxygenated and total hemoglobin).
Changes in amplitude of the photon density wave signals may correspond to the absorptive components of the pulsatile patient tissue, not scattering components. Certain components of the tissue may absorb different wavelengths of light, such as red or infrared light, in different amounts. By analyzing decreases in amplitudes of the received single- wavelength photon density wave signals, a ratio of different types of particles in the pulsatile patient tissue, such as oxygenated and deoxygenated hemoglobin, may be estimated. With measurements of scattering and absorption characteristics of the tissue, physiological parameters such as Sp02, regional oxygen saturation, total hemoglobin, perfusion, and many others may be obtained.
With the foregoing in mind, FIG. 1 illustrates a perspective view of a photon density wave pulse oximetry system 10, which may include a patient monitor 12 and a pulse oximeter sensor 14. A sensor cable 16 may connect the patient monitor 12 to the sensor 14, and may include two fiber optic cables. One of the fiber optic cables within the sensor cable 16 may transmit a multi-wavelength photon density wave input signal from the patient monitor 12 to the sensor 14, and another of the fiber optic cables may transmit a multi-wavelength photon density wave output signal from the sensor 14 to the
patient monitor 12. The cable 16 may couple to the monitor 12 via an optical connection 18. Based on signals received from the sensor 14, the patient monitor 12 may determine certain physiological parameters that may appeal- on a display 20. Such parameters may include, for example, a plethysmogram or numerical representations of patient blood flow (e.g., partial oxygen saturation or a measurement of total hemoglobin).
The patient monitor 12 may modulate light sources of two or more wavelengths at modulation frequencies of approximately 50 MHz - 3GHz, which may produce resolvable photon density wave signals in pulsatile tissue because the resulting photon density waves at such frequencies may have wavelengths shorter than a mean absorption distance in pulsatile tissue. In some embodiments, the patient monitor 12 may sweep the modulation frequency of one or more of the light sources in a range from 50 MHz to 2.4 GHz. Some embodiments of the patient monitor 12 may be configured to modulate between 100 MHz and 1 GHz or to sweep a range from 100 MHz to 1 GHz. The patient monitor 12 may, in certain embodiments, modulate the light sources primarily at a frequency of approximately 500 MHz. Examples of such single- wavelength photon density wave signals that may be generated by the patient monitor 12 may be illustrated below with reference to FIGS. 3 and 4.
The patient monitor 12 may time-division multiplex these several single- wavelength photon density wave signals into a single multi-wavelength photon density signal, in which each of the single-wavelength photon density wave signals is alternatingly the sole wavelength active in the multi-wavelength signal for brief periods of time (e.g., approximately 150 ns to several ms). Generally, these periods of time may be brief enough to enable each of the single-wavelength components of the multi- wavelength signal to pass through the pulsatile tissue at substantially the same time. In
other words, the periods of time may be brief enough such that, for purposes of pulse oximetry, substantially no perceptible change in the pulsatile tissue of the patient may occur between the start of the first single-wavelength component and the start of the last single-wavelength component in the multi-wavelength signal. An example of such a multi-wavelength signal composed of time-division multiplexed single-wavelength signals may be illustrated below with reference to FIG. 5.
The multi-wavelength signal may be provided to the sensor 14 via the sensor cable 16. The sensor 14 may include an emitter output 22 and a detector input 24. The emitter output 22 may guide the multi-wavelength photon density wave signal from the sensor cable 16 to enter pulsatile tissue of a patient 26. The detector input 24 may receive the resulting multi-wavelength photon density signal from the pulsatile tissue of the patient 26 and guide the received signal back to the patient monitor 12 via the sensor cable 16. The sensor 14 may be, for example, a reflectance-type sensor or a
transmission-type sensor.
When the resulting multi- wavelength photon density wave signal reaches the patient monitor 12, the patient monitor 12 may detect and demultiplex the signal into the single-wavelength component signals. Wave characteristics of the received single- wavelength photon density signals may be measured in accordance with present embodiments, and may include characteristics that relate predominantly to absorption of the emitted light in the probed medium (e.g., amplitude change) and characteristics that relate predominantly to scattering in the probed medium (e.g., phase shift). The correlation of certain wave characteristic (e.g., amplitude and phase) measurements to certain medium characteristics (e.g., quantity of scattering particles and blood oxygen saturation) may depend on the modulation of the light sources within the patient monitor,
which may generate resolvable photon density waves. Specifically, to produce resolvable photon density waves, the modulation frequency of such signals should produce photon density waves having modulation wavelengths that are shorter than a mean absorption distance of the probed tissue medium.
As indicated above, the system 10 may be utilized to make measurements that relate predominantly to scattering in the observed volume. More specifically, the system 10 may be utilized to make measurements relating to a total amount of scattering particles in the observed volume based on phase shifts detected in the emitted light waves. For example, the system 10 may emit light that is modulated at a frequency (e.g., 50 MHz to 3 GHz) sufficient to generate resolvable photon density waves, and then measure the phase shift of these waves to facilitate estimation of a total number of scattering particles in the observed medium. Similarly, as set forth above, the system 10 may be utilized to make measurements that relate predominantly to absorption in an observed volume. For example, the system 10 may detect changes in AC and DC amplitudes of the resolvable photon density waves to facilitate detection of a ratio of certain constituents in the blood (e.g., a ratio of oxygenated to total hemoglobin). It should be noted that the amplitude changes and phase shifts measured at a detection point may be considered relative to one or more points. For example, the amplitude and phase shifts measured from the detector input 24 may be considered relative to the associated values generated at the emitter output 22.
FIG. 2 represents a block diagram of the system 10 of FIG. 1. As illustrated in FIG. 2, the patient monitor 12 may generate several single-wavelength photon density wave signals at alternating periods of time (e.g., between approximately every 150 ns and several ms) using a driving circuit 28, such that generally only one single-wavelength
photon density wave signal is active at any given time. The period of time that each single-wavelength photon density wave is active may be short enough such that only very slight changes occur in patient 26 pulsatile tissue content. In this way, despite that the several single-wavelength photon density wave signals are not active simultaneously, the alternating pulses of the several single-wavelength signals may occur close enough to one another such that, for medical purposes, they occur at substantially the same time.
The driving circuit 28 may include one or more light sources that may emit at least two different wavelengths of light. Such wavelengths may include red wavelengths of between approximately 600-700 nm and/or infrared wavelengths of between approximately 800- 1000 nm . By way of example, the light sources of the driving circuit 28 may be laser diodes that emit red or infrared light with wavelengths of approximately 660 nm or 808 nm, respectively. In some embodiments, the one or more light sources of the driving circuit 28 may emit three or more different wavelengths light. Such wavelengths may include a red wavelength of between approximately 620-700 nm (e.g., 660 nm), a far red wavelength of between approximately 690-770 nm (e.g., 730 nm), and an infrared wavelength of between approximately 860-940nm (e.g., 900 nm). Other wavelengths that may be emitted by the one or more light sources of the driving circuit 28 may include, for example, wavelengths of between approximately 500-600 nm and/or 1000-1100 nm.
The driving circuit 28 may modulate these light sources at a modulation frequency between approximately 50 MHz to 3 GHz. Such modulation frequencies may suffice to produce resolvable photon density waves when emitted into pulsatile tissue of the patient 26, since corresponding wavelengths of the photon density waves may be shorter than a mean distance of absorption in the tissue. The modulation frequency of
each light source may vaiy, as one light source may have a higher or lower modulation frequency than another light source. The driving circuit 28 may represent one or more components of commonly available drive circuits (e.g., DVD R W driver circuits) for modulation. Examples of such devices may include the LMH6525 device available from National Semiconductor Inc.
In FIG. 2, the driving circuit 28 is illustrated to generate two single-wavelength photon density wave signals of different wavelengths respectively through an optical cable 30 and an optical cable 32. However, it should be appreciated that the driving circuit 28 may be designed to generate any suitable number of single- wavelength signals. A fiber coupler 34 may join the two optical cables 30 and 32 together, multiplexing the two single-wavelength photon density wave signals into one multi-wavelength photon density wave signal. This multi-wavelength photon density wave signal may represent a combination of the several single-wavelength photon density wave signals generated at alternating periods of time by the driving circuit 28 and, as such, may be understood to represent a time-division multiplexed combination of the several single-wavelength photon density wave signals.
An optical cable 36 may carry the multi-wavelength photon density wave signal through the sensor cable 16 to the emitter output 22 of the sensor 14. The multi- wavelength photon density wave signal may thereafter enter pulsatile tissue of the patient 26, where the signal may be scattered and absorbed by various components of the tissue. The detector input 24 may receive and guide the portion of the signals reflected or transmitted through the patient 26 tissue to the patient monitor 12 over an optical cable 38, which may be a second of only two optical cables of the sensor cable 16.
Because the multi-wavelength signal represents a time-division multiplexed combination of the several single-wavelength photon density wave signals, only one of the single-wavelength signals generally may pass through the patient 26 and the optical cable 38 at any given time. As such, the received multi-wavelength photon density wave generally may be photoelectrical ly detected in a single photodetector 40, which may receive and convert the optical signal to an electrical signal, before amplifying the received signal. In certain embodiments involving more than two single-wavelength signals, two or more single-wavelength signals may be passed through the patient 26 at once and wavelength demultiplexed before the overall multi-wavelength photon density wave signal may be time-division demultiplexed.
The resulting signal may enter phase detection circuitry 42, and the output of the phase detection circuitry 42 may be digitized and entered into a processor, such as a digital signal processor (DSP) 44, to be analyzed for phase and amplitude changes. To distinguish between the various single- wavelength signals of the multi- wavelength signal, the driving circuit 28 may provide the phase detection circuitry 42 and the DSP 46 with time-division information to indicate which single-wavelength photon density wave signal is currently being received. Using such time-division information, the phase detection circuitry 42 and the DSP 46 may demultiplex the time-division multiplexed multi-wavelength photon density wave signal into its component single- wavelength signal segments.
By analyzing changes in amplitude and phase between the received single- wavelength photon density wave signals and corresponding emitted single-wavelength photon density wave signals of a particular wavelength of light, absoiption and scattering properties of the patient 26 tissue for that wavelength of light may be determined. To
obtain phase changes corresponding to scattering in the patient 26 tissue, the phase detection circuitry 42 may obtain the received multi-wavelength photon density wave signal from the detector 40, and time-division information, clock signals, and/or reference signals relating to the corresponding original emitted single-wavelength photon density wave signals from the driving circuitry 28. The phase detection circuitry 42 may thereafter detect phase changes between the original emitted signal and the received signal associated with each wavelength. In certain embodiments, the phase detection circuitry 42 and the driving circuit 28 may be individual components of a single semiconductor device, such as a DVD R/W driver circuit. Such devices may include the L H6525 device available from National Semiconductor Inc.
The DSP 44 may receive the output from the phase detection circuitry 42 and time-division information and/or reference signal information from the driver circuit 28. By comparing amplitude changes between the received photon density wave signals and the corresponding emitted photon density wave signals of the same corresponding wavelength of light, absorption properties of the patient 26 tissue for each wavelength of light may be determined. Using the absorption and scattering information associated with the amplitude changes and phase changes of the photon density wave signals passed through the patient 26, the DSP 44 may determine a variety of properties based on algorithms stored in memory on the DSP 44 or received from external sources, such as a microprocessor 46 or other devices via a bus 48. One example of such an algorithm may be described below with reference to FIG. 8.
In general, the DSP 44 may ascertain certain properties of the patient 26 tissue based on the following relationships described below. For a modulation frequency where the product of the frequency and the mean rime between absorption events is much larger
than 1, the change in phase Αφ between two points located a distance r from each other on a tissue bed may be given by the following relation:
where c is the speed of light, ω is the angular frequency of modulation, and μ, is the reduced scattering coefficient. The reduced scattering coefficient for a tissue bed accounts for both blood and surrounding tissue components. This can be written as:
The time varying component of this equation at a single wavelength will generally be only the portion due to arterial blood. The time varying component of this equation at a second wavelength will allow for the deconvolution of the scattering coefficient. The scattering coefficient for blood is related to the hematocrit (HCT) through the following relation:
where g is the anisotropy factor, σ is the scattering cross section of an erythrocyte, Vi is the volume of an erythrocyte and HCT is the hematocrit.
As indicated above, the phase of the photon density waves may be sensitive to changes in the scattering coefficient, while the amplitude of the photon density waves may be sensitive to the concentration of absorbers in the medium. Specifically, with regard to amplitude measurements, the AC amplitude and DC amplitude may yield information about absorption in the volume. Thus, detection of amplitude changes in the photon density waves may be utilized to calculate absorber concentration values in the observed medium, such as blood oxygen saturation values. Such calculations may be
made using a standard ratio of ratios (e.g., ratrat) technique for the constant and modulated values of the photon density wave amplitudes at two wavelengths. Once the ratio of ratios values is obtained, it may be mapped to the saturation from clinical calibration curves. In general, the amplitude of the resulting photon density waves after passing through the patient 26 tissue may be described as follows:
where A0 is the initial amplitude, D is the diffusion coefficient given as is the absoiption coefficient, and rsd is the distance between the
emitter and the detector.
With regard to phase shift measurements, when the wavelength of the photon density waves is less than a mean absorption distance of the pulsatile tissue of the patient 26, the phase becomes almost exclusively a function of the scattering coefficient. While dependent upon the tissue bed being probed, this is generally believed to occur at a modulation frequency in the range of approximately 500 MHz. Thus, the phase shift measurement may yield information about the number of erythrocytes or red blood cells in the local probed volume. The HCT discussed above is proportional to the number of erythrocytes. Accordingly, by sweeping frequencies, a multi-parameter output may be obtained that relates to standard pulse oximetry measurements as well as the puddle
hematocrit. In general, the change in phase of the resulting photon density waves after passing through the patient 26 tissue may be described as follows:
The amplitude and phase at a given frequency may be proportional to the scattering and absorption coefficient at a given wavelength until the product of the frequency and the mean time between absorption events is much larger than 1. When the product of the f equency and the mean time between absorption events is much larger than 1 , the amplitude is a function of the absoiption and phase is only a function of the scattering. Thus, in some embodiments, the driving circuit 28 may perform a frequency sweep over time (e.g., from 100 MHz to 1 GHz) to reduce the error in the determination of a single value of reduced scattering coefficient for the blood and a single value of absoiption coefficient.
In some embodiments, by modulating the light sources at a sufficient frequency, and, thus, facilitating a detectable phase shift that corresponds to scattering particles, present embodiments may provide an extra degree of certainty for blood flow parameter measurements. Indeed, the detected amplitude for the photon density waves may be utilized to calculate traditional pulse oximetry information and the phase may be utilized to con irm that such values are correct (e.g., within a certain range of error). For example, the amplitude information may be utilized to calculate a blood oxygen saturation (SpC^) value and empirical data may indicate that a particular SpC>2 value
should correspond to a particular phase variation at a given frequency. In other words, there may be a certain phase change that should accompany a given increase in absorber observed as a change in amplitude. Various known techniques (e.g., learning based algorithms such as support vector machines, cluster analysis, neural networks, and PCA) based on the measured phase shift and amplitude change may be compared to determine if the amplitude shift and phase shift correlate to a known SpC>2. If both the measured amplitude shift and phase shift correlate to a known SpC^, the measured SpC>2 value may be deemed appropriate and displayed or utilized as a correct Sp02 value. Alternatively, if the measured amplitude shift and phase shift do not agree, the calculated S C value may be identified as being corrupt or including too much noise and, thus, may be discarded.
As shown in FIG. 2, the patient monitor 12 may include a general- or special- purpose microprocessor 46 on the bus 48, which may govern other general operations of the patient monitor 12, such as how data from the DSP 44 is employed by other components on the bus 48. A network interface card (NIC) 50 may enable the patient monitor 12 to communicate with external devices on a network. A read only memoiy (ROM) 52 may store certain algorithms, such as those used by the DSP 44 to determine absoiption and scattering properties of the patient 26 tissue, and nonvolatile storage 54 may store longer long-term data. Additionally or alternatively the nonvolatile storage 54 may also store the algorithms for determining tissue properties.
Other components of the patient monitor 12 may include random access memory
(RAM) 56, a display interface 58, and control inputs 60. The RAM 56 may provide temporary storage of variables and other data employed while carry out certain techniques described herein, while the display interface 58 may allow physiological parameters obtained by the patient monitor 12 to appear on the display 20. The control
inputs 60 may enable a physician or other medical practitioner to vary the operation of the patient monitor 12. By way of example, a practitioner may select whether the patient 26 is an adult or neonate, and/or whether the tissue is high perfusion or low perfusion tissue. Such a selection with the control inputs 60 may vary the modulation frequency of one or more of the single-wavelength photon density wave signals, may disable one or more of the single-wavelength photon density wave signals, or may cause a
preprogrammed sequence of operation, such as a sweep of modulation frequencies for one or more of the single-wavelength photon density wave signals, to begin.
As noted above, the driving circuit 28 may emit several single-wavelength photon density wave signals that may be combined in the fiber coupler 34 into one multi- wavelength photon density wave signal and sent to the sensor 14. Turning to FIG. 3, a plot 62 may describe an embodiment of one single- wavelength component of such a multi-wavelength photon density wave signal. In the plot 62, an ordinate 64 represents relative amplitude, and an abscissa 66 represents relative time. Numeral 68 refers to a first single- wavelength photon density wave signal (e.g., a 660 nm photon density wave signal) generated by the driving circuit 28. It should be understood that the signal 68 may alternatively have a different amplitude, modulation frequency, and/or phase.
The single-wavelength signal 68 may be active at regular intervals for a given period of time (e.g., between approximately 150 ns and 1 ms) for time-division multiplexing with one or more other signals. As noted below with reference to FIGS. 4 and 5, the single-wavelength photon density wave signal 68 may be combined with other single-wavelength signals into a multi-wavelength signal. The driving circuit 28 may thus emit the signal 68 at intervals and for periods of time related to the number of other emitted single-wavelength signals to be combined into the multi-wavelength signal. For
example, if the single- wavelength photon density wave signal 68 is one of two single- wavelength photon density wave signals emitted by the driving circuit 28, the signal 68 may be emitted by the driving circuit 28 approximately half of the time, as shown in the plot 62.
FIG. 4 is a plot 70 that may describe an embodiment of another single- wavelength component of a multi-wavelength photon density wave signal. In the plot 70, an ordinate 72 represents relative amplitude, and an abscissa 74 represents relative time. Numeral 76 refers to a second single-wavelength photon density wave signal (e.g., an 808 nm photon density wave signal) generated by the driving circuit 28. The single- wavelength signal 76 may be active at regular intervals for a given period of time (e.g., between approximately 150 ns and 1 ms) for time-division multiplexing with one or more other photon density wave signals, such as the single-wavelength photon density wave signal 68. In particular, the signal 76 may be active at times when the signal 68 of the plot 62 is not. It should be understood that the signal 76 may alternatively have a different amplitude, modulation frequency, and/or phase.
The single-wavelength photon density wave signals 68 and 76 emitted by the driving circuitry 28 may be combined into a single multi-wavelength photon density wave signal in the fiber coupler 38. FIG. 5 represents a plot 78 illustrating such a multi- wavelength photon density wave signal having time-division multiplexed single- wavelength component signals 68 and 76. In the plot 78, an ordinate 80 represents relative amplitude, and an abscissa 82 represents relative time. The signals 68 and 76 may occur at different, non-overlapping, times in the multi-wavelength signal of the plot 78. In this way, the two single-wavelength photon density wave signals 68 and 76 may
be later separated into distinct single-wavelength signals with time-division
demultiplexing of the plot 78. Although not necessary, a brief dark period 84 (e.g., 3 ns) may separate the two signals 68 and 76.
When the multi-wavelength photon density wave signal of the plot 78 has passed through the pulsatile tissue of the patient 26, single-wavelength component output signals, resulting from the signals 68 and 76, may be isolated in the phase detection circuitry 42 and the DSP 44 with time-division information the driving circuit 28.
Compaving one of the single-wavelength output signals with the corresponding original single- wavelength signal 68 or 76 of the plot 78 may indicate various properties of the patient 26 tissue.
For example, FIG. 6 illustrates the superimposition of a single- wavelength segment of the signal 68 from the multi-wavelength plot 78 with the resulting single- wavelength signal detected after passage through the patient 26. Like the plots 62, 70, and 78 of FIGS. 3-5, plot 86 of FIG. 6 includes an ordinate 88 representing relative amplitude and an abscissa 90 representing time in units of nanoseconds (ns). The input single-wavelength photon density wave signal 68 and a corresponding output single- wavelength photon density wave signal 80 may have a DC amplitude difference of ΔDC1 , an AC amplitude difference of A4C, , and a phase difference of Δφ1 . The amplitude measurements ΔDC1 and ΔAC1 may correspond essentially only to absorption in the patient 26 tissue, while the phase difference Δφ1 may correspond essentially only to scattering in the patient 26 tissue, as generally described with reference to FIG. 8 below.
Since another single-wavelength photon density wave signal, such as the single- wavelength signal 76, may occur very shortly thereafter, performing a similar comparison with the other single-wavelength signal may yield additional measurements for absoiption and scattering properties of the patient 26 for the second wavelength, at substantially the same time. Thus, the patient monitor 12 may determine at least four measurements associated with properties of the patient 26 tissue for substantially the same time for medical purposes associated with pulse oximetry, including two absorption and two scattering properties. In other words, because substantially no perceptible change in the pulsatile tissue of the patient may occur between the start of the first single- wavelength signal 68 and the start of the second single-wavelength signal 76, for purposes of pulse oximetry, the four measur ements may be understood to occur at substantially the same time.
FIG. 7 illustrates a flowchart 94, which represents an embodiment of a method for performing photon density wave measurements using two wavelengths of light. In a first step 96, the driving circuit 28 may modulate a light source emitting a first wavelength (e.g., a 660 nm wavelength) at a modulation frequency sufficient to produce resolvable photon density waves within the patient 26 for a brief period of time (e.g., between approximately 150 ns and 1 ms). The period of time may depend, for example, on the modulation frequency or the number of wavelengths of light that the driving circuit 28 will modulate. Generally, the modulation frequency may result in a photon density wave wavelength shorter than a mean absorption distance of the pulsatile tissue of the patient 26. In other words, such modulation frequency may exceed the product of the mean absorption coefficient multiplied by the speed of light. Thus, depending on the patient 26, the modulation frequency may be between 50 MHz to 3 GHz. In some
embodiments, the light source may be modulated at a frequency of approximately 500 MHz.
In step 98, the first single-wavelength photon density wave signal may enter the fiber coupler 34 before being transmitted to the sensor 14 via the optical cable 36. Only the first single-wavelength signal may travel across the optical cable 36 at this time. The first single-wavelength photon density wave signal may enter pulsatile tissue of the patient 26 through the emitter output 22 of the sensor 14. After the signal has been reflected or transmitted through the patient 26 tissue, the detector input 24 of the sensor 14 may receive and guide the signal to the optical cable 38, which may transmit the signal back to the patient monitor 12.
The output single-wavelength photon density wave signal that results when the first single-wavelength photon density wave signal is passed through the patient 26 may be detected in the detector 40 in step 100. In step 102, the phase detection circuitry 44 may determine phase changes between the output single-wavelength photon density wave signal and the corresponding input single-wavelength photon density wave signal, and the DSP 46 may determine amplitude changes. The DSP 46 and/or microprocessor 48 may thereafter determine various scattering and absorption properties of the patient 26 tissue, since changes in phase may correspond to scattering in the patient 26 tissue, while changes in amplitude may correspond to absoiption. It should be appreciated that step 102 may occur any time after steps 96-100, including concurrently with or after steps 104-108 described below.
Step 104 may generally begin substantially immediately after step 100. In step 104, the driving circuit 28 may modulate a light source emitting a second wavelength in substantially the same manner as in step 96 to produce a second single-wavelength
photon density wave signal. In step 106, the second single- wavelength photon density wave signal may be passed through the patient 26, and in step 108, the output second single-wavelength photon density wave signal may be detected in the detector 40. Step 110 may involve ascertaining phase and amplitude changes between the output second single- wavelength photon density wave signal and the corresponding input single- wavelength photon density wave signal in substantially the same manner as step 102. Step 110 may occur time after steps 104-108.
The flowchart 94 may repeat indefinitely, with step 96 generally beginning after step 108. As the flowchart 94 repeats, the modulation frequency may or may not vaiy among the light sources and may or may not vary over time. Because both the first and second single-wavelength signals may travel across the optical cable 36, but at distinct times, the two signals of different wavelengths may be understood to be time-division multiplexed and may be understood collectively to form a multi-wavelength photon density wave signal.
FIG. 8 is a flowchart 110, which represents an algorithm that may be used by a processor, such as the DSP 44 of the patient monitor 12, to determine physiological properties of the patient 26 tissue using values obtained by passing a multi-wavelength photon density wave signal through the patient 26 tissue. As such, it should be understood that the flowchart 110 may generally begin after all or part of the flowchart 94 of FIG. 7 has been carried out. In a first step 112, phase change Δφ1 and/or amplitude change ΔDC,1 and/or ΔAC1 values for one of the single-wavelength components of the multi-wavelength photon density wave signal may be received into or determined by a processor, such as the DSP 44.
In step 114, the DSP 44 may determine a scattering property of the patient 26 tissue for the moment in time at which the single-wavelength component of the multi- wavelength photon density wave signal has passed through the pulsatile tissue of the patient 26. Generally, the scattering property may be represented by a scattering coefficient, and may be determined based on the phase change Αφ1 value obtained in step 112 by using Equation (1).
In step 116, the DSP 44 may determine an absorption property of the patient 26 tissue for the moment in time at which the single-wavelength component of the multi- wavelength photon density wave signal has passed through the pulsatile tissue of the patient 26. Generally, the absorption property may be represented by an absorption coefficient, and may be determined based on the amplitude change ΔDC1 and/or ΔDC1 values obtained in step 112 by using Equations (1) and (4).
While the embodiments set forth in the present disclosure may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. The disclosure is to cover all modifications, equivalents, and alternatives falling within the spir it and scope of the disclosure as defined by the following appended claims.
Claims
1. A system compiising:
a patient monitor capable of generating a multi-wavelength photon density wave input signal by modulating one or more light sources at one or more modulation frequencies sufficient to produce resolvable photon density waves in pulsatile tissue of a patient, receiving a multi-wavelength photon density wave output signal resulting after the multi-wavelength photon density wave input signal is passed through the pulsatile tissue of the patient, and determining a scattering property and an absorption property of the pulsatile tissue of the patient based at least in part on a comparison between the multi-wavelength photon density wave output signal and the multi-wavelength photon density wave input signal;
a sensor having an emitter output and a detector input, wherein the emitter output is configured to pass the multi-wavelength photon density wave input signal into the pulsatile tissue of the patient and wherein the detector input is configured to receive the multi-wavelength photon density wave output signal from the pulsatile tissue of the patient; and
a sensor cable coupled to the sensor and having a first optical cable capable of transmitting the multi- wavelength photon density wave input signal from the patient monitor to the sensor and having a second optical cable capable of transmitting the multi- wavelength photon density wave output signal from the sensor to the patient monitor.
2. The system of claim 1, wherein the sensor is a transmission-type sensor, a reflectance-type sensor, and/or a combination thereof.
3. The system of claim 1, wherein the sensor cable comprises no more than two optical cables.
4. The system of claim 1 , wherein the sensor cable comprises only one or more optical cables.
5. The system of claim 1 , wherein the one or more light sources comprise a red light source and/or an infrared light source and/or a near infrared light source, or any combination thereof.
6. The system of claim 1 , wherein the patient monitor is capable of generating the multi-wavelength photon density wave input signal by generating and time-division multiplexing a plurality of single-wavelength photon density wave input signals.
7. The system of claim 6, wherein the patient monitor is capable of time- division demultiplexing the multi-wavelength photon density wave output signal to obtain a plurality of single-wavelength photon density wave output signals that corresponds respectively to the plurality of time-division multiplexed single-wavelength photon density wave input signals.
8. The system of claim 7, wherein the patient monitor is capable of determining a physiological parameter of the patient based at least in part on a comparison of one of the plurality of single-wavelength photon density wave output signals to a corresponding one of the plurality of time-division multiplexed single- wavelength photon density wave input signals.
9. The system of claim 7, wherein the patient monitor is capable of determining a physiological parameter of the patient based at least in part on a change in phase between one of the plurality of single-wavelength photon density wave output signals and a corresponding one of the plurality of time-division multiplexed single- wavelength photon density wave input signals.
10. The system of claim 7, wherein the patient monitor is capable of determining a physiological parameter of the patient based at least in part on a change in amplitude between one of the plurality of single-wavelength photon density wave output signals and a corresponding one of the plurality of time-division multiplexed single- wavelength photon density wave input signals.
11. A patient monitor comprising:
one or more light sources capable of emitting a plurality of wavelengths of light;
a driving circuit capable of modulating the one or more light sources at one or more modulation frequencies sufficient to produce resolvable photon density waves in a patient to produce a plurality of single-wavelength photon density wave input signals at non-overlapping intervals;
a fiber coupler capable of combining the plurality of single-wavelength photon density wave input signals into a multi- wavelength photon density wave input signal;
a sensor cable connector capable of providing the multi-wavelength photon density wave input signal to a first optical cable of a medical sensor capable of being attached to the patient and receiving a multi-wavelength photon density wave output signal from a second optical cable of the medical sensor; and data processing circuitry capable of time-division demultiplexing the multi-wavelength photon density wave output signal into a plurality of single- wavelength photon density wave output signals and determining a physiological parameter of the patient based at least in part on a comparison of one of the plurality of single-wavelength photon density wave output signals to a corresponding one of the plurality of single- wavelength photon density wave input signals.
12. The patient monitor of claim 11 , wherein the one or more light sources comprise one or more laser diodes.
13. The patient monitor of claim 11 , wherein the driving circuit is capable of modulating the one or more of light sources at modulation frequencies between 50 MHz and 3 GHz.
14. The patient monitor of claim 11, wherein the driving circuit is capable of modulating the one or more light sources such that each of the plurality of single- wavelength photon density wave input signals has a different respective modulation frequency.
15. The patient monitor of claim 11, wherein the data processing circuitry is capable of determining an absorption property of the patient based at least in part on a change in amplitude between the one of the plurality of single- wavelength photon density wave output signals and the corresponding one of the plurality of single- wavelength photon density wave input signals.
16. The patient monitor of claim 11 , wherein the data processing circuitry is capable of determining an scattering property of the patient based at least in part on a change in phase between the one of the plurality of single-wavelength output photon density wave signals and the corresponding one of the plurality of single-wavelength input photon density wave signals.
17. A method comprising:
generating a first photon density wave signal by modulating a light source of a first wavelength using a driving circuit;
emitting the first photon density wave input signal through the pulsatile tissue of the patient for a first period of time using a sensor coupled to an input optical cable and attached to the patient;
receiving a fust photon density wave output signal that results when the first photon density wave input signal is emitted through the pulsatile tissue of the patient into an output optical cable using the sensor attached to the patient;
generating a second photon density wave signal by modulating a light source of second wavelength at the modulation frequency using the driving circuit;
emitting the second photon density wave input signal through the pulsatile tissue of the patient for a second period of time using the sensor coupled to the input optical cable and attached to the patient, wherein the first period of time and the second period of time do not overlap;
receiving a second photon density wave output signal that results when the second photon density wave input signal is emitted through the pulsatile tissue of the patient into the output optical cable using the sensor attached to the patient; and
comparing phases and/or amplitudes of the first and second photon density wave output signals to respective phases of the first and second photon density wave input signals to determine a scattering property and/or an absoiption property of the pulsatile tissue of the patient using phase detection circuitry, signal processing circuitry, and/or data processing circuitry.
18. The method of claim 17, wherein the second photon density wave signal is emitted for the second period of time, wherein the second period of time begins immediately after the first period of time or following a dark period after the first period of time.
19. The method of claim 18, wherein the second photon density wave signal is emitted for the second period of time, wherein the second period of time and the first period of time are sufficiently brief such that substantially no perceptible change in the pulsatile tissue of the patient has occurred between the start of the first period of time and the start of the second period of time.
20. The method of claim 17, wherein the second photon density wave signal is emitted for the second period of time, wherein the second period of time occupies the same quantity of time as the first period of time.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10760148A EP2480123A2 (en) | 2009-09-21 | 2010-08-25 | Time-division multiplexing in a multi-wavelength photon density wave system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/563,852 US8788001B2 (en) | 2009-09-21 | 2009-09-21 | Time-division multiplexing in a multi-wavelength photon density wave system |
US12/563,852 | 2009-09-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011034699A2 true WO2011034699A2 (en) | 2011-03-24 |
WO2011034699A3 WO2011034699A3 (en) | 2011-07-07 |
Family
ID=43037917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/046674 WO2011034699A2 (en) | 2009-09-21 | 2010-08-25 | Time-division multiplexing in a multi-wavelength photon density wave system |
Country Status (3)
Country | Link |
---|---|
US (1) | US8788001B2 (en) |
EP (1) | EP2480123A2 (en) |
WO (1) | WO2011034699A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011123239A1 (en) * | 2010-03-31 | 2011-10-06 | Nellcor Puritan Bennett Llc | Multi-wavelength photon density wave system using an optical switch |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8386000B2 (en) | 2008-09-30 | 2013-02-26 | Covidien Lp | System and method for photon density wave pulse oximetry and pulse hemometry |
US8401608B2 (en) | 2009-09-30 | 2013-03-19 | Covidien Lp | Method of analyzing photon density waves in a medical monitor |
US9675250B2 (en) * | 2010-11-01 | 2017-06-13 | Oxirate, Inc. | System and method for measurement of vital signs of a human |
US8712492B2 (en) | 2011-05-31 | 2014-04-29 | Covidien Lp | Photon density wave based determination of physiological blood parameters |
US20120310062A1 (en) * | 2011-05-31 | 2012-12-06 | Nellcor Puritan Bennett Llc | Photon density wave based determination of physiological blood parameters |
US20130109941A1 (en) * | 2011-10-28 | 2013-05-02 | Nellcor Puritan Bennett Llc | Methods and systems for photoacoustic signal processing |
US9055869B2 (en) * | 2011-10-28 | 2015-06-16 | Covidien Lp | Methods and systems for photoacoustic signal processing |
US9326684B2 (en) | 2011-11-08 | 2016-05-03 | Covidien Lp | Magnetic enhancement in determination of physiological blood parameters |
US8886294B2 (en) * | 2011-11-30 | 2014-11-11 | Covidien Lp | Methods and systems for photoacoustic monitoring using indicator dilution |
US20130137960A1 (en) * | 2011-11-30 | 2013-05-30 | Nellcor Puritan Bennett Llc | Methods and systems for photoacoustic monitoring using indicator dilution |
US9131852B2 (en) | 2011-12-05 | 2015-09-15 | Covidien Lp | Methods and systems for photoacoustic monitoring using indicator dilution |
US10123711B2 (en) | 2012-01-10 | 2018-11-13 | Maxim Integrated Products, Inc. | Heart rate and blood oxygen monitoring system |
US9833146B2 (en) | 2012-04-17 | 2017-12-05 | Covidien Lp | Surgical system and method of use of the same |
US9050044B2 (en) | 2012-06-12 | 2015-06-09 | Covidien Lp | Pathlength enhancement of optical measurement of physiological blood parameters |
US9380981B2 (en) | 2013-03-15 | 2016-07-05 | Covidien Lp | Photoacoustic monitoring technique with noise reduction |
Family Cites Families (203)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3638640A (en) | 1967-11-01 | 1972-02-01 | Robert F Shaw | Oximeter and method for in vivo determination of oxygen saturation in blood using three or more different wavelengths |
US4281645A (en) | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4938218A (en) | 1983-08-30 | 1990-07-03 | Nellcor Incorporated | Perinatal pulse oximetry sensor |
US4714341A (en) | 1984-02-23 | 1987-12-22 | Minolta Camera Kabushiki Kaisha | Multi-wavelength oximeter having a means for disregarding a poor signal |
IT1206462B (en) | 1984-08-07 | 1989-04-27 | Anic Spa | MULTI-WAVE LENGTH PULSED LIGHT PHOTOMETER FOR NON-INVASIVE MONITORING. |
ZA861179B (en) | 1985-02-28 | 1986-12-30 | Boc Group Inc | Oximeter |
US4911167A (en) | 1985-06-07 | 1990-03-27 | Nellcor Incorporated | Method and apparatus for detecting optical pulses |
US4936679A (en) | 1985-11-12 | 1990-06-26 | Becton, Dickinson And Company | Optical fiber transducer driving and measuring circuit and method for using same |
US4913150A (en) | 1986-08-18 | 1990-04-03 | Physio-Control Corporation | Method and apparatus for the automatic calibration of signals employed in oximetry |
US4805623A (en) | 1987-09-04 | 1989-02-21 | Vander Corporation | Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment |
US4807631A (en) | 1987-10-09 | 1989-02-28 | Critikon, Inc. | Pulse oximetry system |
EP0315040B1 (en) | 1987-11-02 | 1993-01-27 | Sumitomo Electric Industries Limited | Bio-photosensor |
JPH0288041A (en) | 1988-09-24 | 1990-03-28 | Misawahoomu Sogo Kenkyusho:Kk | Finger tip pulse wave sensor |
US5564417A (en) | 1991-01-24 | 1996-10-15 | Non-Invasive Technology, Inc. | Pathlength corrected oximeter and the like |
CA1331483C (en) | 1988-11-02 | 1994-08-16 | Britton Chance | User-wearable hemoglobinometer for measuring the metabolic condition of a subject |
US4972331A (en) | 1989-02-06 | 1990-11-20 | Nim, Inc. | Phase modulated spectrophotometry |
US5873821A (en) | 1992-05-18 | 1999-02-23 | Non-Invasive Technology, Inc. | Lateralization spectrophotometer |
US5122974A (en) | 1989-02-06 | 1992-06-16 | Nim, Inc. | Phase modulated spectrophotometry |
EP0374668A3 (en) | 1988-12-16 | 1992-02-05 | A.W. Faber - Castell GmbH & Co. | Fluorescent marking fluid |
US5553614A (en) | 1988-12-21 | 1996-09-10 | Non-Invasive Technology, Inc. | Examination of biological tissue using frequency domain spectroscopy |
US5119815A (en) | 1988-12-21 | 1992-06-09 | Nim, Incorporated | Apparatus for determining the concentration of a tissue pigment of known absorbance, in vivo, using the decay characteristics of scintered electromagnetic radiation |
US5555885A (en) | 1988-12-21 | 1996-09-17 | Non-Invasive Technology, Inc. | Examination of breast tissue using time-resolved spectroscopy |
US5353799A (en) | 1991-01-22 | 1994-10-11 | Non Invasive Technology, Inc. | Examination of subjects using photon migration with high directionality techniques |
US5028787A (en) | 1989-01-19 | 1991-07-02 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US6708048B1 (en) | 1989-02-06 | 2004-03-16 | Non-Invasive Technology, Inc. | Phase modulation spectrophotometric apparatus |
US6183414B1 (en) | 1999-04-26 | 2001-02-06 | Michael S. Wysor | Technique for restoring plasticity to tissues of a male or female organ |
US5483646A (en) | 1989-09-29 | 1996-01-09 | Kabushiki Kaisha Toshiba | Memory access control method and system for realizing the same |
US5190038A (en) | 1989-11-01 | 1993-03-02 | Novametrix Medical Systems, Inc. | Pulse oximeter with improved accuracy and response time |
DE3938759A1 (en) | 1989-11-23 | 1991-05-29 | Philips Patentverwaltung | NON-INVASIVE OXIMETER ARRANGEMENT |
NZ238717A (en) | 1990-06-27 | 1994-08-26 | Futrex Inc | Blood glucose level measured by transmitting near-infrared energy through body part |
US5372136A (en) | 1990-10-06 | 1994-12-13 | Noninvasive Medical Technology Corporation | System and method for noninvasive hematocrit monitoring |
US6681128B2 (en) | 1990-10-06 | 2004-01-20 | Hema Metrics, Inc. | System for noninvasive hematocrit monitoring |
US6266546B1 (en) | 1990-10-06 | 2001-07-24 | In-Line Diagnostics Corporation | System for noninvasive hematocrit monitoring |
US6246894B1 (en) | 1993-02-01 | 2001-06-12 | In-Line Diagnostics Corporation | System and method for measuring blood urea nitrogen, blood osmolarity, plasma free hemoglobin and tissue water content |
EP0574509B1 (en) | 1991-03-07 | 1999-09-15 | Masimo Corporation | Signal processing apparatus and method |
US5995855A (en) | 1998-02-11 | 1999-11-30 | Masimo Corporation | Pulse oximetry sensor adapter |
US5638818A (en) | 1991-03-21 | 1997-06-17 | Masimo Corporation | Low noise optical probe |
US6580086B1 (en) | 1999-08-26 | 2003-06-17 | Masimo Corporation | Shielded optical probe and method |
DE4138702A1 (en) | 1991-03-22 | 1992-09-24 | Madaus Medizin Elektronik | METHOD AND DEVICE FOR THE DIAGNOSIS AND QUANTITATIVE ANALYSIS OF APNOE AND FOR THE SIMULTANEOUS DETERMINATION OF OTHER DISEASES |
US6549795B1 (en) | 1991-05-16 | 2003-04-15 | Non-Invasive Technology, Inc. | Spectrophotometer for tissue examination |
JP3124073B2 (en) | 1991-08-27 | 2001-01-15 | 日本コーリン株式会社 | Blood oxygen saturation monitor |
US5246003A (en) | 1991-08-28 | 1993-09-21 | Nellcor Incorporated | Disposable pulse oximeter sensor |
US5247931A (en) | 1991-09-16 | 1993-09-28 | Mine Safety Appliances Company | Diagnostic sensor clasp utilizing a slot, pivot and spring hinge mechanism |
WO1993013706A2 (en) | 1992-01-17 | 1993-07-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Optical method for monitoring arterial blood hematocrit |
ATE171027T1 (en) | 1992-01-25 | 1998-09-15 | Alsthom Cge Alcatel | METHOD FOR FACILITATING THE OPERATION OF TERMINAL DEVICES IN TELEVISION SYSTEMS |
US5385143A (en) | 1992-02-06 | 1995-01-31 | Nihon Kohden Corporation | Apparatus for measuring predetermined data of living tissue |
US5297548A (en) | 1992-02-07 | 1994-03-29 | Ohmeda Inc. | Arterial blood monitoring probe |
US5263244A (en) | 1992-04-17 | 1993-11-23 | Gould Inc. | Method of making a flexible printed circuit sensor assembly for detecting optical pulses |
JP3170866B2 (en) | 1992-04-24 | 2001-05-28 | 株式会社ノーリツ | 1 can 2 circuit type instant heating type heat exchanger |
EP0572684B1 (en) | 1992-05-15 | 1996-07-03 | Hewlett-Packard GmbH | Medical sensor |
US6785568B2 (en) | 1992-05-18 | 2004-08-31 | Non-Invasive Technology Inc. | Transcranial examination of the brain |
US5355880A (en) | 1992-07-06 | 1994-10-18 | Sandia Corporation | Reliable noninvasive measurement of blood gases |
US5680857A (en) | 1992-08-28 | 1997-10-28 | Spacelabs Medical, Inc. | Alignment guide system for transmissive pulse oximetry sensors |
US5460182A (en) * | 1992-09-14 | 1995-10-24 | Sextant Medical Corporation | Tissue penetrating apparatus and methods |
EP0684575A4 (en) | 1993-12-14 | 1997-05-14 | Mochida Pharm Co Ltd | Medical measuring apparatus. |
US5492118A (en) | 1993-12-16 | 1996-02-20 | Board Of Trustees Of The University Of Illinois | Determining material concentrations in tissues |
US5497769A (en) | 1993-12-16 | 1996-03-12 | I.S.S. (Usa) Inc. | Photosensor with multiple light sources |
US5645059A (en) | 1993-12-17 | 1997-07-08 | Nellcor Incorporated | Medical sensor with modulated encoding scheme |
JP3238813B2 (en) | 1993-12-20 | 2001-12-17 | テルモ株式会社 | Pulse oximeter |
JP3464697B2 (en) | 1993-12-21 | 2003-11-10 | 興和株式会社 | Oxygen saturation meter |
US5995859A (en) | 1994-02-14 | 1999-11-30 | Nihon Kohden Corporation | Method and apparatus for accurately measuring the saturated oxygen in arterial blood by substantially eliminating noise from the measurement signal |
DE4423597C1 (en) | 1994-07-06 | 1995-08-10 | Hewlett Packard Gmbh | Pulsoximetric ear sensor |
US5692503A (en) | 1995-03-10 | 1997-12-02 | Kuenstner; J. Todd | Method for noninvasive (in-vivo) total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination |
US7035697B1 (en) | 1995-05-30 | 2006-04-25 | Roy-G-Biv Corporation | Access control systems and methods for motion control |
US5758644A (en) | 1995-06-07 | 1998-06-02 | Masimo Corporation | Manual and automatic probe calibration |
US5645060A (en) | 1995-06-14 | 1997-07-08 | Nellcor Puritan Bennett Incorporated | Method and apparatus for removing artifact and noise from pulse oximetry |
US6095974A (en) * | 1995-07-21 | 2000-08-01 | Respironics, Inc. | Disposable fiber optic probe |
US5995856A (en) | 1995-11-22 | 1999-11-30 | Nellcor, Incorporated | Non-contact optical monitoring of physiological parameters |
SE9600322L (en) | 1996-01-30 | 1997-07-31 | Hoek Instr Ab | Sensor for pulse oximetry with fiber optic signal transmission |
US5840023A (en) | 1996-01-31 | 1998-11-24 | Oraevsky; Alexander A. | Optoacoustic imaging for medical diagnosis |
DE59704665D1 (en) | 1996-04-01 | 2001-10-25 | Linde Medical Sensors Ag Basel | DETECTION OF INTERFERENCE SIGNALS IN PULSOXYMETRIC MEASUREMENT |
US5842981A (en) | 1996-07-17 | 1998-12-01 | Criticare Systems, Inc. | Direct to digital oximeter |
US6163715A (en) | 1996-07-17 | 2000-12-19 | Criticare Systems, Inc. | Direct to digital oximeter and method for calculating oxygenation levels |
IL120881A (en) | 1996-07-30 | 2002-09-12 | It M R Medic L Cm 1997 Ltd | Method and apparatus for the non-invasive continous monitoring of peripheral arterial tone |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US5830139A (en) | 1996-09-04 | 1998-11-03 | Abreu; Marcio M. | Tonometer system for measuring intraocular pressure by applanation and/or indentation |
US6120460A (en) | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
US5871442A (en) | 1996-09-10 | 1999-02-16 | International Diagnostics Technologies, Inc. | Photonic molecular probe |
US6081742A (en) | 1996-09-10 | 2000-06-27 | Seiko Epson Corporation | Organism state measuring device and relaxation instructing device |
DE19640807A1 (en) | 1996-10-02 | 1997-09-18 | Siemens Ag | Noninvasive optical detection of oxygen supply to e.g. brain or liver |
US5830136A (en) | 1996-10-31 | 1998-11-03 | Nellcor Puritan Bennett Incorporated | Gel pad optical sensor |
US6122042A (en) | 1997-02-07 | 2000-09-19 | Wunderman; Irwin | Devices and methods for optically identifying characteristics of material objects |
US6487439B1 (en) | 1997-03-17 | 2002-11-26 | Victor N. Skladnev | Glove-mounted hybrid probe for tissue type recognition |
AUPO676397A0 (en) | 1997-05-13 | 1997-06-05 | Dunlop, Colin | Method and apparatus for monitoring haemodynamic function |
IL121079A0 (en) * | 1997-06-15 | 1997-11-20 | Spo Medical Equipment Ltd | Physiological stress detector device and method |
BR9810143A (en) | 1997-06-17 | 2001-11-27 | Respironics Inc | Fetal oximetry system and sensor |
AU7934498A (en) | 1997-06-27 | 1999-01-19 | Toa Medical Electronics Co., Ltd. | Living body inspecting apparatus and noninvasive blood analyzer using the same |
FI973454A (en) | 1997-08-22 | 1999-02-23 | Instrumentarium Oy | A resilient device in a measuring sensor for observing the properties of living tissue |
EP0864293B1 (en) | 1997-12-22 | 1999-08-04 | Hewlett-Packard Company | Telemetry system, in particular for medical purposes |
JP3567319B2 (en) | 1997-12-26 | 2004-09-22 | 日本光電工業株式会社 | Probe for pulse oximeter |
ATE416668T1 (en) | 1998-02-05 | 2008-12-15 | Hema Metrics Inc | METHOD AND DEVICE FOR NON-INVASIVE OBSERVATION OF BLOOD COMPONENTS |
JP3576851B2 (en) | 1998-03-23 | 2004-10-13 | キヤノン株式会社 | Liquid crystal display, video camera |
US6662030B2 (en) | 1998-05-18 | 2003-12-09 | Abbott Laboratories | Non-invasive sensor having controllable temperature feature |
IL124787A0 (en) | 1998-06-07 | 1999-01-26 | Itamar Medical C M 1997 Ltd | Pressure applicator devices particularly useful for non-invasive detection of medical conditions |
US5920263A (en) | 1998-06-11 | 1999-07-06 | Ohmeda, Inc. | De-escalation of alarm priorities in medical devices |
WO2000009004A2 (en) | 1998-08-13 | 2000-02-24 | Whitland Research Limited | Optical device |
US6671526B1 (en) | 1998-07-17 | 2003-12-30 | Nihon Kohden Corporation | Probe and apparatus for determining concentration of light-absorbing materials in living tissue |
JP2000083933A (en) | 1998-07-17 | 2000-03-28 | Nippon Koden Corp | Instrument for measuring concentration of light absorptive material in vital tissue |
US6949081B1 (en) | 1998-08-26 | 2005-09-27 | Non-Invasive Technology, Inc. | Sensing and interactive drug delivery |
US6064898A (en) | 1998-09-21 | 2000-05-16 | Essential Medical Devices | Non-invasive blood component analyzer |
JP3950243B2 (en) * | 1998-11-05 | 2007-07-25 | 浜松ホトニクス株式会社 | Method and apparatus for measuring internal information of scattering medium |
WO2000028887A1 (en) | 1998-11-18 | 2000-05-25 | Alfons Krug | Device for non-invasively detecting the oxygen metabolism in tissues |
US6352502B1 (en) | 1998-12-03 | 2002-03-05 | Lightouch Medical, Inc. | Methods for obtaining enhanced spectroscopic information from living tissue, noninvasive assessment of skin condition and detection of skin abnormalities |
US6606511B1 (en) | 1999-01-07 | 2003-08-12 | Masimo Corporation | Pulse oximetry pulse indicator |
US6684090B2 (en) | 1999-01-07 | 2004-01-27 | Masimo Corporation | Pulse oximetry data confidence indicator |
US6658276B2 (en) | 1999-01-25 | 2003-12-02 | Masimo Corporation | Pulse oximeter user interface |
US6438399B1 (en) | 1999-02-16 | 2002-08-20 | The Children's Hospital Of Philadelphia | Multi-wavelength frequency domain near-infrared cerebral oximeter |
US6360114B1 (en) | 1999-03-25 | 2002-03-19 | Masimo Corporation | Pulse oximeter probe-off detector |
US6675029B2 (en) | 1999-07-22 | 2004-01-06 | Sensys Medical, Inc. | Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy |
US7904139B2 (en) | 1999-08-26 | 2011-03-08 | Non-Invasive Technology Inc. | Optical examination of biological tissue using non-contact irradiation and detection |
US6618042B1 (en) | 1999-10-28 | 2003-09-09 | Gateway, Inc. | Display brightness control method and apparatus for conserving battery power |
JP2001149349A (en) | 1999-11-26 | 2001-06-05 | Nippon Koden Corp | Sensor for living body |
US6622095B2 (en) | 1999-11-30 | 2003-09-16 | Nihon Kohden Corporation | Apparatus for determining concentrations of hemoglobins |
US6415236B2 (en) | 1999-11-30 | 2002-07-02 | Nihon Kohden Corporation | Apparatus for determining concentrations of hemoglobins |
EP2308374B1 (en) | 1999-12-22 | 2012-07-18 | Orsense Ltd. | A method of optical measurements for determining various parameters of the patient's blood |
US6419671B1 (en) | 1999-12-23 | 2002-07-16 | Visx, Incorporated | Optical feedback system for vision correction |
US6594513B1 (en) | 2000-01-12 | 2003-07-15 | Paul D. Jobsis | Method and apparatus for determining oxygen saturation of blood in body organs |
US7006676B1 (en) | 2000-01-21 | 2006-02-28 | Medical Optical Imaging, Inc. | Method and apparatus for detecting an abnormality within a host medium utilizing frequency-swept modulation diffusion tomography |
IL135077A0 (en) | 2000-03-15 | 2001-05-20 | Orsense Ltd | A probe for use in non-invasive measurements of blood related parameters |
US6453183B1 (en) * | 2000-04-10 | 2002-09-17 | Stephen D. Walker | Cerebral oxygenation monitor |
PT2322085E (en) | 2000-04-17 | 2014-06-23 | Covidien Lp | Pulse oximeter sensor with piece-wise function |
US6516209B2 (en) | 2000-08-04 | 2003-02-04 | Photonify Technologies, Inc. | Self-calibrating optical imaging system |
US6801648B2 (en) | 2000-08-04 | 2004-10-05 | Xuefeng Cheng | Optical imaging system with symmetric optical probe |
US6889153B2 (en) | 2001-08-09 | 2005-05-03 | Thomas Dietiker | System and method for a self-calibrating non-invasive sensor |
IL138683A0 (en) | 2000-09-25 | 2001-10-31 | Vital Medical Ltd | Apparatus and method for monitoring tissue vitality parameters |
WO2002026194A2 (en) | 2000-09-28 | 2002-04-04 | Non-Invasive Monitoring Systems, Inc. | External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention |
IL138884A (en) | 2000-10-05 | 2006-07-05 | Conmed Corp | Pulse oximeter and a method of its operation |
US6513209B1 (en) * | 2000-10-13 | 2003-02-04 | Nike, Inc. | Fastening system for a bra |
US6466809B1 (en) | 2000-11-02 | 2002-10-15 | Datex-Ohmeda, Inc. | Oximeter sensor having laminated housing with flat patient interface surface |
US6985763B2 (en) * | 2001-01-19 | 2006-01-10 | Tufts University | Method for measuring venous oxygen saturation |
US6501974B2 (en) | 2001-01-22 | 2002-12-31 | Datex-Ohmeda, Inc. | Compensation of human variability in pulse oximetry |
US7239902B2 (en) | 2001-03-16 | 2007-07-03 | Nellor Puritan Bennett Incorporated | Device and method for monitoring body fluid and electrolyte disorders |
US6591122B2 (en) | 2001-03-16 | 2003-07-08 | Nellcor Puritan Bennett Incorporated | Device and method for monitoring body fluid and electrolyte disorders |
US6606509B2 (en) | 2001-03-16 | 2003-08-12 | Nellcor Puritan Bennett Incorporated | Method and apparatus for improving the accuracy of noninvasive hematocrit measurements |
US6898451B2 (en) | 2001-03-21 | 2005-05-24 | Minformed, L.L.C. | Non-invasive blood analyte measuring system and method utilizing optical absorption |
US20020156354A1 (en) | 2001-04-20 | 2002-10-24 | Larson Eric Russell | Pulse oximetry sensor with improved spring |
ATE369787T1 (en) | 2001-06-20 | 2007-09-15 | Purdue Research Foundation | PRESSURE CUFF WITH BODY ILLUMINATION FOR USE IN OPTICAL NON-INVASIVE MEASUREMENT OF BLOOD PARAMETERS |
SG126677A1 (en) | 2001-06-26 | 2006-11-29 | Meng Ting Choon | Method and device for measuring blood sugar level |
US6697658B2 (en) | 2001-07-02 | 2004-02-24 | Masimo Corporation | Low power pulse oximeter |
DE10139379A1 (en) | 2001-08-10 | 2003-03-06 | Siemens Ag | Inductive motion sensor has sensor coils beside permanent magnet field generator |
US6654621B2 (en) | 2001-08-29 | 2003-11-25 | Bci, Inc. | Finger oximeter with finger grip suspension system |
US6668183B2 (en) | 2001-09-11 | 2003-12-23 | Datex-Ohmeda, Inc. | Diode detection circuit |
IL145445A (en) | 2001-09-13 | 2006-12-31 | Conmed Corp | Signal processing method and device for signal-to-noise improvement |
US7162306B2 (en) | 2001-11-19 | 2007-01-09 | Medtronic Physio - Control Corp. | Internal medical device communication bus |
JP3709836B2 (en) | 2001-11-20 | 2005-10-26 | コニカミノルタセンシング株式会社 | Blood component measuring device |
JP2003194714A (en) | 2001-12-28 | 2003-07-09 | Omega Wave Kk | Measuring apparatus for blood amount in living-body tissue |
JP2003210438A (en) | 2002-01-22 | 2003-07-29 | Tyco Healthcare Japan Inc | Adapter for oximeter |
US6822564B2 (en) | 2002-01-24 | 2004-11-23 | Masimo Corporation | Parallel measurement alarm processor |
DE60315596T2 (en) | 2002-01-31 | 2008-05-15 | Loughborough University Enterprises Ltd., Loughborough | VENOUS PULSE OXIMETRY |
WO2003068070A1 (en) | 2002-02-14 | 2003-08-21 | Toshinori Kato | Apparatus for evaluating biological function |
DE60332094D1 (en) | 2002-02-22 | 2010-05-27 | Masimo Corp | ACTIVE PULSE SPECTROPHOTOMETRY |
WO2003073924A1 (en) | 2002-03-01 | 2003-09-12 | Terry Beaumont | Ear canal sensing device |
US6863652B2 (en) | 2002-03-13 | 2005-03-08 | Draeger Medical Systems, Inc. | Power conserving adaptive control system for generating signal in portable medical devices |
JP2003275192A (en) | 2002-03-25 | 2003-09-30 | Citizen Watch Co Ltd | Blood analyzer |
DE10213692B4 (en) | 2002-03-27 | 2013-05-23 | Weinmann Diagnostics Gmbh & Co. Kg | Method for controlling a device and device for measuring ingredients in the blood |
US6690958B1 (en) | 2002-05-07 | 2004-02-10 | Nostix Llc | Ultrasound-guided near infrared spectrophotometer |
US6711425B1 (en) | 2002-05-28 | 2004-03-23 | Ob Scientific, Inc. | Pulse oximeter with calibration stabilization |
JP2003339678A (en) | 2002-05-30 | 2003-12-02 | Minolta Co Ltd | Instrument for measuring blood state |
JP4040913B2 (en) | 2002-06-07 | 2008-01-30 | 株式会社パルメディカル | Noninvasive arteriovenous oxygen saturation measuring device |
US7024235B2 (en) | 2002-06-20 | 2006-04-04 | University Of Florida Research Foundation, Inc. | Specially configured nasal pulse oximeter/photoplethysmography probes, and combined nasal probe/cannula, selectively with sampler for capnography, and covering sleeves for same |
US6909912B2 (en) | 2002-06-20 | 2005-06-21 | University Of Florida | Non-invasive perfusion monitor and system, specially configured oximeter probes, methods of using same, and covers for probes |
AU2003242975B2 (en) | 2002-07-15 | 2008-04-17 | Itamar Medical Ltd. | Body surface probe, apparatus and method for non-invasively detecting medical conditions |
JP2004202190A (en) | 2002-11-08 | 2004-07-22 | Minolta Co Ltd | Biological information measuring device |
WO2004047631A2 (en) | 2002-11-22 | 2004-06-10 | Masimo Laboratories, Inc. | Blood parameter measurement system |
JP3944448B2 (en) | 2002-12-18 | 2007-07-11 | 浜松ホトニクス株式会社 | Blood measuring device |
JP4284674B2 (en) | 2003-01-31 | 2009-06-24 | 日本光電工業株式会社 | Absorbent concentration measuring device in blood |
WO2004069046A1 (en) | 2003-02-05 | 2004-08-19 | Philips Intellectual Property & Standards Gmbh | Finger medical sensor |
JP2004248819A (en) | 2003-02-19 | 2004-09-09 | Citizen Watch Co Ltd | Blood analyzer |
EP1628571B1 (en) | 2003-02-27 | 2011-08-24 | Nellcor Puritan Bennett Ireland | Method and system for analysing and processing photoplethysmogram signals using wavelet transform analysis |
DE10311408B3 (en) | 2003-03-13 | 2004-09-02 | Universität Zu Lübeck | Non-invasive measurement of blood component concentrations, e.g. for monitoring patients in an emergency, comprises using light with a pulsed ultrasonic beam to detect backscattered light for evaluation |
JP2004290544A (en) | 2003-03-28 | 2004-10-21 | Citizen Watch Co Ltd | Blood analyzer |
JP2004290545A (en) | 2003-03-28 | 2004-10-21 | Citizen Watch Co Ltd | Blood analyzer |
US6947780B2 (en) | 2003-03-31 | 2005-09-20 | Dolphin Medical, Inc. | Auditory alarms for physiological data monitoring |
KR100571811B1 (en) | 2003-05-09 | 2006-04-17 | 삼성전자주식회사 | Ear type measurement apparatus for bio signal |
US7047056B2 (en) | 2003-06-25 | 2006-05-16 | Nellcor Puritan Bennett Incorporated | Hat-based oximeter sensor |
US8602986B2 (en) | 2003-08-20 | 2013-12-10 | Koninklijke Philips N.V. | System and method for detecting signal artifacts |
EP1675501B1 (en) | 2003-09-12 | 2013-09-04 | Or-Nim Medical Ltd. | Noninvasive optical monitoring of region of interest |
US7373193B2 (en) | 2003-11-07 | 2008-05-13 | Masimo Corporation | Pulse oximetry data capture system |
US20050113651A1 (en) | 2003-11-26 | 2005-05-26 | Confirma, Inc. | Apparatus and method for surgical planning and treatment monitoring |
EP1700100A1 (en) | 2003-12-22 | 2006-09-13 | Koninklijke Philips Electronics N.V. | Optical analysis system, blood analysis system and method of determining an amplitude of a principal component |
US20050267346A1 (en) | 2004-01-30 | 2005-12-01 | 3Wave Optics, Llc | Non-invasive blood component measurement system |
WO2005077260A1 (en) | 2004-02-12 | 2005-08-25 | Biopeak Corporation | Non-invasive method and apparatus for determining a physiological parameter |
US7277741B2 (en) | 2004-03-09 | 2007-10-02 | Nellcor Puritan Bennett Incorporated | Pulse oximetry motion artifact rejection using near infrared absorption by water |
US20050209516A1 (en) | 2004-03-22 | 2005-09-22 | Jacob Fraden | Vital signs probe |
JP4191642B2 (en) | 2004-04-02 | 2008-12-03 | 三菱電機株式会社 | Transflective liquid crystal display device and manufacturing method thereof |
US20050228248A1 (en) | 2004-04-07 | 2005-10-13 | Thomas Dietiker | Clip-type sensor having integrated biasing and cushioning means |
US8082015B2 (en) | 2004-04-13 | 2011-12-20 | The Trustees Of The University Of Pennsylvania | Optical measurement of tissue blood flow, hemodynamics and oxygenation |
US7375347B2 (en) | 2004-04-26 | 2008-05-20 | Sensors For Medicine And Science, Inc. | Systems and methods for extending the useful life of optical sensors |
US7164938B2 (en) | 2004-06-21 | 2007-01-16 | Purdue Research Foundation | Optical noninvasive vital sign monitor |
US7551950B2 (en) | 2004-06-29 | 2009-06-23 | O2 Medtech, Inc,. | Optical apparatus and method of use for non-invasive tomographic scan of biological tissues |
US7343186B2 (en) | 2004-07-07 | 2008-03-11 | Masimo Laboratories, Inc. | Multi-wavelength physiological monitor |
US7225005B2 (en) | 2004-12-14 | 2007-05-29 | Intelligent Medical Devices, Inc. | Optical determination of in vivo properties |
US20060129038A1 (en) | 2004-12-14 | 2006-06-15 | Zelenchuk Alex R | Optical determination of in vivo properties |
PL1863387T3 (en) | 2005-03-16 | 2013-11-29 | Or Nim Medical Ltd | Noninvasive measurements in a human body |
DE102005013429A1 (en) | 2005-03-21 | 2006-09-28 | Flore, Ingo, Dr. | Mobile diagnostic device |
US7548771B2 (en) | 2005-03-31 | 2009-06-16 | Nellcor Puritan Bennett Llc | Pulse oximetry sensor and technique for using the same on a distal region of a patient's digit |
KR100716824B1 (en) | 2005-04-28 | 2007-05-09 | 삼성전기주식회사 | Printed circuit board with embedded capacitors using hybrid materials, and manufacturing process thereof |
WO2006124696A1 (en) | 2005-05-13 | 2006-11-23 | Children's Hospital Medical Center | Multi-wavelength spatial domain near infrared oximeter to detect cerebral hypoxia-ischemia |
US7330746B2 (en) | 2005-06-07 | 2008-02-12 | Chem Image Corporation | Non-invasive biochemical analysis |
US7378954B2 (en) | 2005-10-21 | 2008-05-27 | Barry Myron Wendt | Safety indicator and method |
US20070093702A1 (en) | 2005-10-26 | 2007-04-26 | Skyline Biomedical, Inc. | Apparatus and method for non-invasive and minimally-invasive sensing of parameters relating to blood |
US20080220512A1 (en) | 2007-03-09 | 2008-09-11 | Nellcor Puritan Bennett Llc | Tunable laser-based spectroscopy system for non-invasively measuring body water content |
JP5049624B2 (en) | 2007-03-26 | 2012-10-17 | 株式会社東芝 | Metal fine particle dispersed film and method for producing metal fine particle dispersed film |
-
2009
- 2009-09-21 US US12/563,852 patent/US8788001B2/en active Active
-
2010
- 2010-08-25 WO PCT/US2010/046674 patent/WO2011034699A2/en active Application Filing
- 2010-08-25 EP EP10760148A patent/EP2480123A2/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2480123A2 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011123239A1 (en) * | 2010-03-31 | 2011-10-06 | Nellcor Puritan Bennett Llc | Multi-wavelength photon density wave system using an optical switch |
US8391943B2 (en) | 2010-03-31 | 2013-03-05 | Covidien Lp | Multi-wavelength photon density wave system using an optical switch |
Also Published As
Publication number | Publication date |
---|---|
EP2480123A2 (en) | 2012-08-01 |
US8788001B2 (en) | 2014-07-22 |
US20110071373A1 (en) | 2011-03-24 |
WO2011034699A3 (en) | 2011-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8788001B2 (en) | Time-division multiplexing in a multi-wavelength photon density wave system | |
US8386000B2 (en) | System and method for photon density wave pulse oximetry and pulse hemometry | |
CA2186225C (en) | Pulse oximeter and sensor optimized for low saturation | |
US9433362B2 (en) | Analyzing photon density waves in a medical monitor | |
US7415298B2 (en) | Pulse oximeter and sensor optimized for low saturation | |
US11116412B2 (en) | Robust, clinical-grade transabdominal fetal pulse oximetry | |
US8433382B2 (en) | Transmission mode photon density wave system and method | |
US8391943B2 (en) | Multi-wavelength photon density wave system using an optical switch | |
US20120310060A1 (en) | Method of analyzing photon density waves in a medical monitor | |
US7848891B2 (en) | Modulation ratio determination with accommodation of uncertainty | |
US20110071366A1 (en) | Determination Of A Physiological Parameter | |
US8494604B2 (en) | Wavelength-division multiplexing in a multi-wavelength photon density wave system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10760148 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2010760148 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010760148 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |